WO2021251452A1 - 光線性皮膚疾患の予防又は治療剤 - Google Patents
光線性皮膚疾患の予防又は治療剤 Download PDFInfo
- Publication number
- WO2021251452A1 WO2021251452A1 PCT/JP2021/022048 JP2021022048W WO2021251452A1 WO 2021251452 A1 WO2021251452 A1 WO 2021251452A1 JP 2021022048 W JP2021022048 W JP 2021022048W WO 2021251452 A1 WO2021251452 A1 WO 2021251452A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- substituted
- optionally substituted
- alkyl
- groups
- Prior art date
Links
- 208000017520 skin disease Diseases 0.000 title claims abstract description 27
- 239000003814 drug Substances 0.000 title claims description 22
- 230000003449 preventive effect Effects 0.000 title description 4
- 229940124597 therapeutic agent Drugs 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 58
- 206010047642 Vitiligo Diseases 0.000 claims abstract description 45
- 230000000694 effects Effects 0.000 claims abstract description 38
- 150000003839 salts Chemical class 0.000 claims abstract description 30
- 230000008099 melanin synthesis Effects 0.000 claims abstract description 29
- 241000097929 Porphyria Species 0.000 claims abstract description 21
- 208000010642 Porphyrias Diseases 0.000 claims abstract description 20
- 230000001737 promoting effect Effects 0.000 claims abstract description 15
- 238000001126 phototherapy Methods 0.000 claims abstract description 13
- 208000003367 Hypopigmentation Diseases 0.000 claims abstract description 4
- 230000003425 hypopigmentation Effects 0.000 claims abstract description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 137
- -1 aminosulfonylaminocarbonyl group Chemical group 0.000 claims description 117
- 125000003545 alkoxy group Chemical group 0.000 claims description 75
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 69
- 125000005843 halogen group Chemical group 0.000 claims description 56
- 125000001072 heteroaryl group Chemical group 0.000 claims description 56
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 52
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 49
- 125000001931 aliphatic group Chemical group 0.000 claims description 47
- 125000000623 heterocyclic group Chemical group 0.000 claims description 46
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 43
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 43
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 37
- 125000001188 haloalkyl group Chemical group 0.000 claims description 36
- 125000004043 oxo group Chemical group O=* 0.000 claims description 35
- 125000003118 aryl group Chemical group 0.000 claims description 32
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 31
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 30
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 25
- 125000005529 alkyleneoxy group Chemical group 0.000 claims description 24
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims description 23
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 22
- 125000001424 substituent group Chemical group 0.000 claims description 22
- 201000010099 disease Diseases 0.000 claims description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 21
- 125000003386 piperidinyl group Chemical group 0.000 claims description 21
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 20
- 125000002950 monocyclic group Chemical group 0.000 claims description 20
- 125000002252 acyl group Chemical group 0.000 claims description 19
- 239000013078 crystal Substances 0.000 claims description 19
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 17
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 17
- 229940079593 drug Drugs 0.000 claims description 16
- 210000004209 hair Anatomy 0.000 claims description 16
- 208000011580 syndromic disease Diseases 0.000 claims description 16
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 15
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 13
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 13
- 201000008220 erythropoietic protoporphyria Diseases 0.000 claims description 12
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 11
- 208000002440 photoallergic dermatitis Diseases 0.000 claims description 11
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 11
- 125000003107 substituted aryl group Chemical group 0.000 claims description 11
- 208000012641 Pigmentation disease Diseases 0.000 claims description 10
- 125000003277 amino group Chemical group 0.000 claims description 10
- 206010036182 Porphyria acute Diseases 0.000 claims description 8
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 8
- 206010010356 Congenital anomaly Diseases 0.000 claims description 7
- 208000027816 DNA repair disease Diseases 0.000 claims description 7
- 208000026748 Hypopigmentation disease Diseases 0.000 claims description 7
- 206010034972 Photosensitivity reaction Diseases 0.000 claims description 7
- 230000036211 photosensitivity Effects 0.000 claims description 7
- 125000003342 alkenyl group Chemical group 0.000 claims description 6
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 6
- 125000004966 cyanoalkyl group Chemical group 0.000 claims description 6
- 230000002065 hypopigmenting effect Effects 0.000 claims description 5
- 125000005017 substituted alkenyl group Chemical group 0.000 claims description 5
- 208000005452 Acute intermittent porphyria Diseases 0.000 claims description 4
- 208000000627 Hereditary Coproporphyria Diseases 0.000 claims description 4
- 201000006083 Xeroderma Pigmentosum Diseases 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 125000001589 carboacyl group Chemical group 0.000 claims description 4
- 208000005692 Bloom Syndrome Diseases 0.000 claims description 3
- 206010052465 Congenital poikiloderma Diseases 0.000 claims description 3
- 208000019872 Drug Eruptions Diseases 0.000 claims description 3
- 201000004315 EAST syndrome Diseases 0.000 claims description 3
- 208000010201 Exanthema Diseases 0.000 claims description 3
- 208000017605 Hodgkin disease nodular sclerosis Diseases 0.000 claims description 3
- 201000011252 Phenylketonuria Diseases 0.000 claims description 3
- 208000000791 Rothmund-Thomson syndrome Diseases 0.000 claims description 3
- 208000024780 Urticaria Diseases 0.000 claims description 3
- 208000025749 Vogt-Koyanagi-Harada disease Diseases 0.000 claims description 3
- 201000011032 Werner Syndrome Diseases 0.000 claims description 3
- 230000005856 abnormality Effects 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 201000005884 exanthem Diseases 0.000 claims description 3
- 208000037824 growth disorder Diseases 0.000 claims description 3
- 230000003779 hair growth Effects 0.000 claims description 3
- 208000007583 hydroa vacciniforme Diseases 0.000 claims description 3
- 210000002445 nipple Anatomy 0.000 claims description 3
- 208000017983 photosensitivity disease Diseases 0.000 claims description 3
- 206010037844 rash Diseases 0.000 claims description 3
- 230000033616 DNA repair Effects 0.000 claims description 2
- 206010073508 Drug reaction with eosinophilia and systemic symptoms Diseases 0.000 claims description 2
- 102100032865 General transcription factor IIH subunit 5 Human genes 0.000 claims description 2
- 101000655402 Homo sapiens General transcription factor IIH subunit 5 Proteins 0.000 claims description 2
- 206010044628 Trichothiodystrophy Diseases 0.000 claims description 2
- 208000003059 Trichothiodystrophy Syndromes Diseases 0.000 claims description 2
- 208000001445 Uveomeningoencephalitic Syndrome Diseases 0.000 claims description 2
- 201000008230 cutaneous porphyria Diseases 0.000 claims description 2
- 238000011282 treatment Methods 0.000 abstract description 10
- 230000002265 prevention Effects 0.000 abstract description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 52
- 125000004433 nitrogen atom Chemical group N* 0.000 description 49
- 210000003491 skin Anatomy 0.000 description 49
- 238000012360 testing method Methods 0.000 description 37
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 36
- 125000004430 oxygen atom Chemical group O* 0.000 description 35
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 32
- 229910052717 sulfur Inorganic materials 0.000 description 32
- 125000004434 sulfur atom Chemical group 0.000 description 32
- 102000008314 Type 1 Melanocortin Receptor Human genes 0.000 description 31
- 108010021428 Type 1 Melanocortin Receptor Proteins 0.000 description 30
- UAHFGYDRQSXQEB-LEBBXHLNSA-N afamelanotide Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 UAHFGYDRQSXQEB-LEBBXHLNSA-N 0.000 description 28
- 229940126062 Compound A Drugs 0.000 description 27
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 27
- 210000004027 cell Anatomy 0.000 description 24
- 238000000034 method Methods 0.000 description 24
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 24
- 102000005962 receptors Human genes 0.000 description 24
- 108020003175 receptors Proteins 0.000 description 24
- 239000000126 substance Substances 0.000 description 23
- 125000001153 fluoro group Chemical group F* 0.000 description 22
- 239000000243 solution Substances 0.000 description 22
- 125000004432 carbon atom Chemical group C* 0.000 description 20
- 125000005842 heteroatom Chemical group 0.000 description 20
- 229910052731 fluorine Inorganic materials 0.000 description 18
- 238000011156 evaluation Methods 0.000 description 17
- 108700034262 4-Nle-7-Phe-alpha- MSH Proteins 0.000 description 15
- 125000004076 pyridyl group Chemical group 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 13
- 102000004378 Melanocortin Receptors Human genes 0.000 description 13
- 108090000950 Melanocortin Receptors Proteins 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 12
- 125000004429 atom Chemical group 0.000 description 12
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 12
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 125000000714 pyrimidinyl group Chemical group 0.000 description 11
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 description 11
- 239000000556 agonist Substances 0.000 description 10
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 10
- 125000002757 morpholinyl group Chemical group 0.000 description 10
- 125000000168 pyrrolyl group Chemical group 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 229910052801 chlorine Inorganic materials 0.000 description 9
- 125000001309 chloro group Chemical group Cl* 0.000 description 9
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 125000004193 piperazinyl group Chemical group 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 230000037303 wrinkles Effects 0.000 description 9
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 8
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 8
- 125000002393 azetidinyl group Chemical group 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 229940095074 cyclic amp Drugs 0.000 description 8
- 238000011534 incubation Methods 0.000 description 8
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 8
- 239000011534 wash buffer Substances 0.000 description 8
- 102400000740 Melanocyte-stimulating hormone alpha Human genes 0.000 description 7
- 101710200814 Melanotropin alpha Proteins 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 206010051246 Photodermatosis Diseases 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 7
- 125000002971 oxazolyl group Chemical group 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 125000003226 pyrazolyl group Chemical group 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 7
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 102000030612 Melanocortin 5 receptor Human genes 0.000 description 6
- 108010088565 Melanocortin 5 receptor Proteins 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 6
- 210000002752 melanocyte Anatomy 0.000 description 6
- 201000001441 melanoma Diseases 0.000 description 6
- 125000001624 naphthyl group Chemical group 0.000 description 6
- 230000008845 photoaging Effects 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 125000003831 tetrazolyl group Chemical group 0.000 description 6
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
- 102000012422 Collagen Type I Human genes 0.000 description 5
- 108010022452 Collagen Type I Proteins 0.000 description 5
- 239000007995 HEPES buffer Substances 0.000 description 5
- 101000978431 Homo sapiens Melanocortin receptor 3 Proteins 0.000 description 5
- 101000978418 Homo sapiens Melanocortin receptor 4 Proteins 0.000 description 5
- 102100023726 Melanocortin receptor 3 Human genes 0.000 description 5
- 102100023724 Melanocortin receptor 4 Human genes 0.000 description 5
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 125000001715 oxadiazolyl group Chemical group 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 125000003373 pyrazinyl group Chemical group 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- 125000004305 thiazinyl group Chemical group S1NC(=CC=C1)* 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 125000004306 triazinyl group Chemical group 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- MUNWOYRHJPWQNE-GMFUQMJFSA-N dersimelagon Chemical compound C1(CCCC1)N1C[C@@]([C@@H](C1)C1=CC=C(C=C1)OC)(F)C(=O)N1C[C@@H]([C@H](C1)COC)C1=C(C=C(C=C1)C(F)(F)F)N1CCC(CC1)C(=O)O MUNWOYRHJPWQNE-GMFUQMJFSA-N 0.000 description 4
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 4
- 230000004761 fibrosis Effects 0.000 description 4
- 125000002636 imidazolinyl group Chemical group 0.000 description 4
- 125000002883 imidazolyl group Chemical group 0.000 description 4
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000019612 pigmentation Effects 0.000 description 4
- 125000002098 pyridazinyl group Chemical group 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 238000000967 suction filtration Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 125000001984 thiazolidinyl group Chemical group 0.000 description 4
- 125000000335 thiazolyl group Chemical group 0.000 description 4
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 3
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 3
- 230000005778 DNA damage Effects 0.000 description 3
- 231100000277 DNA damage Toxicity 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 101001134060 Homo sapiens Melanocyte-stimulating hormone receptor Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 3
- 208000000453 Skin Neoplasms Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 3
- 125000002947 alkylene group Chemical group 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 3
- 229960000258 corticotropin Drugs 0.000 description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 102000054812 human MC1R Human genes 0.000 description 3
- 125000001183 hydrocarbyl group Chemical group 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 229930195734 saturated hydrocarbon Natural products 0.000 description 3
- 201000000849 skin cancer Diseases 0.000 description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 108010014402 tyrosinase-related protein-1 Proteins 0.000 description 3
- 102100022455 Adrenocorticotropic hormone receptor Human genes 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 208000019300 CLIPPERS Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000678419 Homo sapiens Adrenocorticotropic hormone receptor Proteins 0.000 description 2
- 101800001751 Melanocyte-stimulating hormone alpha Proteins 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 206010042496 Sunburn Diseases 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001270 agonistic effect Effects 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000013262 cAMP assay Methods 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 208000021930 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids Diseases 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 125000004672 ethylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C(*)=O 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- SRJOCJYGOFTFLH-UHFFFAOYSA-N isonipecotic acid Chemical compound OC(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-N 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 208000002741 leukoplakia Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000002287 radioligand Substances 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 125000003003 spiro group Chemical group 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical group CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- PWMJMEIYKSAHGO-WHBPCUIOSA-N C1(CCCC1)N1C[C@@]([C@@H](C1)C1=CC=C(C=C1)OC)(F)C(=O)N1C[C@@H](C[C@H]1COC)C1=C(C=C(C=C1)C(F)(F)F)N1CCC(CC1)C(=O)O Chemical compound C1(CCCC1)N1C[C@@]([C@@H](C1)C1=CC=C(C=C1)OC)(F)C(=O)N1C[C@@H](C[C@H]1COC)C1=C(C=C(C=C1)C(F)(F)F)N1CCC(CC1)C(=O)O PWMJMEIYKSAHGO-WHBPCUIOSA-N 0.000 description 1
- WAYJOJDZKWGILB-ZDFFLLIKSA-N C1(CCCCC1)N1C[C@@]([C@@H](C1)C1=CC=C(C=C1)OC)(F)C(=O)N1C[C@@H](C[C@H]1COC)C1=C(C=C(C=C1)C(F)(F)F)N1CCC(CC1)C(=O)O Chemical compound C1(CCCCC1)N1C[C@@]([C@@H](C1)C1=CC=C(C=C1)OC)(F)C(=O)N1C[C@@H](C[C@H]1COC)C1=C(C=C(C=C1)C(F)(F)F)N1CCC(CC1)C(=O)O WAYJOJDZKWGILB-ZDFFLLIKSA-N 0.000 description 1
- 0 CCC(CC1)CC(C2CCCCC2)C1(*)C(*1CCC(C)(C)C(*)CC1)=C Chemical compound CCC(CC1)CC(C2CCCCC2)C1(*)C(*1CCC(C)(C)C(*)CC1)=C 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- ZWRSFUKRQYWDOK-CJIOBZFESA-N ClC=1C=CC(=C(C=1)N1CCC(CC1)C(=O)O)[C@H]1CN(C[C@@H]1COC)C(=O)[C@@]1(CN(C[C@H]1C1=CC=C(C=C1)OC)[C@@H]1CC[C@H](CC1)OC)F Chemical compound ClC=1C=CC(=C(C=1)N1CCC(CC1)C(=O)O)[C@H]1CN(C[C@@H]1COC)C(=O)[C@@]1(CN(C[C@H]1C1=CC=C(C=C1)OC)[C@@H]1CC[C@H](CC1)OC)F ZWRSFUKRQYWDOK-CJIOBZFESA-N 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 235000005956 Cosmos caudatus Nutrition 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 238000001061 Dunnett's test Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- QIYYHJGHLTXSSO-CCINWMQUSA-N FC=1C=CC(=C(C=1)N1CCC(CC1)C(=O)O)[C@H]1CN([C@@H](C1)COC)C(=O)[C@@]1(CN(C[C@H]1C1=CC=C(C=C1)OC)[C@@H]1CC[C@H](CC1)OC)F Chemical compound FC=1C=CC(=C(C=1)N1CCC(CC1)C(=O)O)[C@H]1CN([C@@H](C1)COC)C(=O)[C@@]1(CN(C[C@H]1C1=CC=C(C=C1)OC)[C@@H]1CC[C@H](CC1)OC)F QIYYHJGHLTXSSO-CCINWMQUSA-N 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 101100456320 Homo sapiens NR3C2 gene Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 102400000744 Melanotropin gamma Human genes 0.000 description 1
- 101800000520 Melanotropin gamma Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 238000009193 PUVA therapy Methods 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108091093078 Pyrimidine dimer Proteins 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 206010040829 Skin discolouration Diseases 0.000 description 1
- 206010041303 Solar dermatitis Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 208000034705 Vogt-Koyanagi-Harada syndrome Diseases 0.000 description 1
- 208000026724 Waardenburg syndrome Diseases 0.000 description 1
- OMOVVBIIQSXZSZ-UHFFFAOYSA-N [6-(4-acetyloxy-5,9a-dimethyl-2,7-dioxo-4,5a,6,9-tetrahydro-3h-pyrano[3,4-b]oxepin-5-yl)-5-formyloxy-3-(furan-3-yl)-3a-methyl-7-methylidene-1a,2,3,4,5,6-hexahydroindeno[1,7a-b]oxiren-4-yl] 2-hydroxy-3-methylpentanoate Chemical compound CC12C(OC(=O)C(O)C(C)CC)C(OC=O)C(C3(C)C(CC(=O)OC4(C)COC(=O)CC43)OC(C)=O)C(=C)C32OC3CC1C=1C=COC=1 OMOVVBIIQSXZSZ-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 108700026906 afamelanotide Proteins 0.000 description 1
- 229960005075 afamelanotide Drugs 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000005115 alkyl carbamoyl group Chemical group 0.000 description 1
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000001058 brown pigment Substances 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 230000011382 collagen catabolic process Effects 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000005046 dihydronaphthyl group Chemical group 0.000 description 1
- 125000004655 dihydropyridinyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000009986 erectile function Effects 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000003499 exocrine gland Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000002795 fluorescence method Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 230000031774 hair cycle Effects 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 229940116364 hard fat Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 125000004129 indan-1-yl group Chemical group [H]C1=C([H])C([H])=C2C(=C1[H])C([H])([H])C([H])([H])C2([H])* 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000000938 luteal effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000000336 melanocortin receptor agonist Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 208000009928 nephrosis Diseases 0.000 description 1
- 231100001027 nephrosis Toxicity 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 231100000760 phototoxic Toxicity 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- OHEDMAIVEXQCOZ-UHFFFAOYSA-N piperidine;dihydrochloride Chemical compound Cl.Cl.C1CCNCC1 OHEDMAIVEXQCOZ-UHFFFAOYSA-N 0.000 description 1
- 235000021018 plums Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000013635 pyrimidine dimer Substances 0.000 description 1
- 150000003235 pyrrolidines Chemical class 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000005437 stratosphere Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 125000005415 substituted alkoxy group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 125000006168 tricyclic group Chemical group 0.000 description 1
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- GZWUQPQBOGLSIM-VOOUCTBASA-N γ msh Chemical compound C([C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(O)=O)C(C)C)C1=CC=C(O)C=C1 GZWUQPQBOGLSIM-VOOUCTBASA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Definitions
- the present invention relates to a pharmaceutical composition for treating or preventing light-induced skin diseases and the like using a compound having melanocortin receptor (MCR) activating activity (agonist activity).
- MCR melanocortin receptor
- actinic skin disease a disease that causes pathological changes such as dermatitis by light irradiation to the extent that it does not react in a healthy person. Actinic skin diseases can be classified into the following four categories. Photoallergic dermatitis, DNA repair abnormalities, porphyria, hydroa vacciniforme. The most primitive treatment for actinic skin disease is shading.
- melanin a brown pigment deposited on the skin as a physiological reaction when the human body is irradiated with ultraviolet rays.
- This is a type of biological defense reaction that protects cells from DNA damage caused by UV rays.
- the cells that produce melanin are called melanocytes, and their progenitor cells are produced in the hair follicles and localized in the hair follicles, and at the same time, they migrate to the basal layer of the epidermis of the skin.
- Melanocytes play an important role in determining human hair color, iridescent color, and skin color.
- ⁇ -MSH in vivo ligand ⁇ -melanocyte stimulating hormone
- M1R melanocortin receptor 1
- MCR Melanocortin receptor
- GPCR G-protein-coupled receptor
- cAMP intracellular cyclic AMP
- MC1R is a receptor mainly activated by ⁇ -MSH and is expressed in melanocytes, immune / inflammatory cells, fibroblasts, keratin-producing cells, endothelial cells, glial cells and the like. Therefore, it is known that when MC1R is activated in the living body, various biological reactions occur. For example, as one phenomenon, the cAMP level rises in the cells expressing MC1R, and the cAMP level is increased. As a result, it is known to exert various effects such as melanin formation in the skin, maintenance of homeostasis against external stimuli, anti-inflammatory action, and tissue fibrosis inhibitory action.
- MC2R has a low response to ⁇ -MSH, is a receptor mainly activated by ACTH, and is highly expressed in the adrenal cortex. It is known that activation of MC2R has a steroid-producing effect.
- MC3R is a receptor mainly activated by ⁇ -MSH and ACTH, and is expressed in the central nervous system, macrophages, and the like. It is known that activation of MC3R exerts effects such as regulation of autonomic nervous function and anti-inflammatory action.
- MC4R is a receptor mainly activated by ⁇ -MSH and ACTH, and is expressed in the central nervous system and the like. Therefore, it is known that activation of MC4R has effects such as suppression of feeding and enhancement of erectile function.
- MC5R is a receptor mainly activated by ⁇ -MSH and is expressed in exocrine glands, lymphocytes, etc. It is known that activation of MC5R has effects such as regulation of exocrine fluid and regulation of immune function. Thus, by activating these melanocortin receptors (MCRs), it is expected that effects such as immunomodulation, anti-inflammatory, and suppression of tissue fibrosis can be obtained through the formation of cAMP.
- MCRs melanocortin receptors
- MCR is divided into subtypes, and each subtype has a different function, and each subtype also has various actions downstream of signal transduction. Therefore, side effects are suppressed and the desired pharmacological action is efficiently performed. In order to exert it, it is important to control the target receptor with a substance that induces a specific and purposeful action.
- Patent Documents 1 to 6 disclose Afamelanotide, which is a substance that is not selective for MC1R but activates MCR including MC1R and can be used for the purpose of treating photoinduced skin diseases and reducing side effects of phototherapy. ing.
- afamelanothide is not an MC1R selective agonist, there is a concern that side effects may occur, and since it is a peptide, it cannot be orally administered, and it has a short half-life and requires regular subcutaneous implants by healthcare professionals. There's a problem.
- Patent Documents 7 and 8 1- ⁇ 2-[(3S, 4R) -1- ⁇ [(3R, 4R) -1-cyclopentyl-3-fluoro-4- (4-methoxyphenyl) pyrrolidine-3) -Il] carbonyl ⁇ -4- (methoxymethyl) pyrrolidine-3-yl] -5- (trifluoromethyl) phenyl ⁇ piperidine-4-carboxylic acid and other pyrrolidine compounds or pharmaceutically acceptable salts thereof, Japanese products Alternatively, it is disclosed that the co-crystal has an excellent activating action of MCR, particularly MC1R.
- the compound is useful for the prevention or treatment of various diseases or symptoms associated with the activation of MCR, particularly MC1R, specifically, rheumatoid arthritis, gouty arthritis, and osteoarthritis of the art.
- Inflammatory bowel disease, systemic rheumatoid arthritis, psoriasis, fibrosis, protoporphyllinosis, systemic erythematosus, melanoma skin cancer, leukoplakia, hair loss, pain, ischemia / reperfusion injury, inflammatory brain Diseases, hepatitis, septic / septic shock, nephritis, transplantation, exacerbation of HIV disease, vasculitis, vasculitis, retinal pigment degeneration, age-related luteal degeneration, microbial psoriasis, celiac disease, nephrosis syndrome, or melanoma infiltration It is listed.
- the present inventors have conducted diligent studies to solve the above problems. As a result, it was found that the compound represented by the following general formula [I] or a pharmaceutically acceptable salt or cocrystal thereof efficiently promotes melanin production in vivo and promotes skin pigmentation. .. As a result, it is effective in preventing and treating light skin diseases (excluding protoporphyria), hypopigmentation diseases (excluding vitiligo (vitiligo vulgaris)), side effects of phototherapy, and gray hair. We have also found a dose that is particularly effective for pigmentation in humans. Based on these findings, the present invention has been completed.
- the present invention contains a compound represented by the following general formula [I] or a pharmaceutically acceptable salt or co-crystal thereof as an active ingredient, and is a state that can be treated or prevented mainly by promoting melanin production (proto).
- a drug for treating or preventing porphyrinosis and vitiligo excluding vitiligo vulgaris.
- the present invention comprises a step of administering to a subject in need of treatment or prevention an effective amount of a compound represented by the following general formula [I] or a pharmaceutically acceptable salt or cocrystal thereof, mainly for melanin production.
- the present invention is represented by the following general formula [I] for treating or preventing a condition that can be treated or prevented mainly by promoting melanin production (excluding protoporphyria or vitiligo (vitiligo vulgaris)).
- a compound to be used or a pharmaceutically acceptable salt or cocrystal thereof is provided.
- the present invention is a condition (protoporphyria or vitiligo) in which a compound represented by the following general formula [I] or a pharmaceutically acceptable salt or cocrystal thereof can be treated or prevented mainly by promoting melanin production.
- a compound represented by the following general formula [I] is 1- ⁇ 2-[(3S, 4R) -1- ⁇ [(3R, 4R) -1-cyclopentyl-3-fluoro-4- (4-methoxy).
- Phenyl) pyrrolidine-3-yl] carbonyl ⁇ -4- (methoxymethyl) pyrrolidine-3-yl] -5- (trifluoromethyl) phenyl ⁇ piperidine-4-carboxylic acid or a pharmaceutically acceptable salt thereof or co- Crystals are preferable.
- Conditions that can be treated or prevented by promoting melanin production include photogenic skin diseases (excluding protoporphyria), hypopigmenting diseases (excluding vitiligo (vitiligo vulgaris)), and side effects of phototherapy.
- Examples of light-induced skin diseases include photoallergic dermatitis, sputum-like vesicular disease, DNA repair disorders, and porphyria (excluding protoporphyria).
- examples of photoallergic dermatitis include porphyria porphyria, polymorphic porphyria, chronic photodermatitis, photoallergic contact dermatitis, photoallergic photosensitivity type drug eruption, and DNA repair disorders.
- Examples include xeroderma pigmentosum, cocaine syndrome, bloom syndrome, Werner syndrome, Rothmund-Thomson syndrome, sulfur-deficient hair growth disorder, photosensitivity syndrome, etc., and porphyria (excluding protoporphyria)
- porphyria examples thereof include congenital myeloid porphyria, atypical porphyria, acute intermittent porphyria, late cutaneous porphyria, and hereditary coproporphyria.
- photoallergic dermatitis such as sun urticaria and polymorphic sun rash, congenital myeloid porphyria, atypical porphyria, acute intermittent porphyria, late skin porphyria, hereditary coproporphyria, etc.
- hypopigmented diseases excluding protoporphyria
- DNA repair disorders such as pigmented porphyria
- hypopigmented diseases excluding vitiligo (vitiligo vulgaris)
- ocular cutaneous vitiligo mottled disease
- depigmented mother's spot hypopigmentation (Ito vitiligo)
- phenylketonuria nodular sclerosis.
- Congenital hypopigmentation disorders such as illness, hereditary contralateral dyschromia, Wardenburg syndrome, Hermannsky-Pudrac syndrome, Chediak-East syndrome, Glyceri syndrome, Teats syndrome, and Sutton vitiligo, Vogt-Koyanagi- Examples include acquired hypopigmentation diseases such as Harada disease, senile vitiligo, vitiligo after bathing, and vitiligo toxic to plums.
- the dose of the compound represented by the general formula [I] or a pharmaceutically acceptable salt or cocrystal thereof is preferably 50 to 500 mg / day, more preferably 100 to 300 mg / day. ..
- the present invention it is possible to efficiently promote melanin production and promote skin pigmentation without the need to be exposed to ultraviolet rays such as the sun's rays, and to activate MC1R centered on its action.
- ultraviolet rays such as the sun's rays
- MC1R centered on its action.
- the compound represented by the general formula [I] or a pharmaceutically acceptable salt or co-crystal thereof can be orally administered, has good pharmacokinetics in humans, and has side effects because it is an MC1R-selective compound. It is possible to treat and prevent light-induced skin diseases, hypopigmented diseases, side effects of phototherapy, gray hair, etc. safely and effectively without burdening the patient.
- FIG. 1 is a diagram showing the results of a melanin production assay using compound A or NDP- ⁇ MSH in mouse melanoma-derived cell line B16F1 cells.
- EC50 activity values were 13.00 and 8.455 pmol / L, respectively, for compound A and NDP- ⁇ MSH. Each value represents the average value ⁇ standard error of the experiments performed three times. * And ** indicate P ⁇ 0.05 and P ⁇ 0.01, respectively.
- FIG. 2 is a diagram showing changes in skin melanin density in which compound A was repeatedly administered to healthy subjects for 14 days and observed until the 57th day.
- FIG. 3 shows the time course of the skin wrinkle score when compound B or HP-228 (control drug, melanocortinergic peptide (Neuropeptides 1997, 31, 565)) was administered in the UV A-irradiated mouse photoaging model. Each value represents the average value ⁇ standard error of 10 cases. ** indicates P ⁇ 0.01 between the untreated group and the solvent control group. # And ## indicate P ⁇ 0.05 and P ⁇ 0.01 in the test substance administration group compared with the solvent control group, respectively.
- FIG. 4 shows the amount of type I collagen in the excised skin after administration of compound B or HP-228 (control drug, melanocortinergic peptide) for 8 weeks in an ultraviolet A-irradiated mouse photoaging model. Each value represents the average value ⁇ standard error of 10 cases. ** indicates P ⁇ 0.01 between the untreated group and the solvent control group. ## indicates P ⁇ 0.01 of the test substance administration group compared with the solvent control group.
- alkyl refers to a linear or branched saturated hydrocarbon chain group having 1 to 6 carbon atoms (C1 to 6)
- a group having 1 to 4 carbon atoms (C1 to 4) is preferable.
- methyl, ethyl, n-propyl, i-propyl, n-butyl, t-butyl, 2-methyl-n-butyl, i-amyl (3-methyl-n-butyl), 2-methyl- Examples include n-pentyl.
- alkenyl refers to a linear or branched hydrocarbon chain group having at least one double bond and having 2 to 6 carbon atoms (C2 to 6).
- C2 to 6 carbon atoms
- a group having 2 to 4 carbon atoms (C2 to 4) can be mentioned.
- Specific examples thereof include vinyl, propenyl, butenyl and the like.
- the cycloalkyl refers to a monocyclic saturated hydrocarbon group having 3 to 7 carbon atoms (C3 to 7) and adamantyl, and specific examples thereof include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and adamantyl.
- the cycloalkenyl refers to a cyclic group having at least one double bond and having 3 to 7 carbon atoms (C3 to 7). Specific examples thereof include cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl and the like.
- Alkoxy refers to a monovalent group in which the above-mentioned alkyl is bonded to an oxygen atom, and examples thereof include linear or branched alkyl-O- having 1 to 6 carbon atoms (C1 to 6) and having 1 to 4 carbon atoms. Alkoxy-O- of (C1-4) is preferable. Specific examples thereof include methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, t-butoxy, 2-methyl-n-propoxy, 3-methyl-n-butoxy and the like.
- the alkylene refers to a linear or branched saturated hydrocarbon divalent group having 1 to 6 carbon atoms (C1 to 6), and a group having 1 to 4 carbon atoms (C1 to 4) is preferable. Specific examples thereof include methylene, ethylene, trimethylene (propylene) and tetramethylene (n-butylene).
- the alkyleneoxy refers to a divalent group in which an oxygen atom is bonded to the above-mentioned alkylene, and specific examples thereof include alkylene-O— having 1 to 6 carbon atoms (C1 to 6) and 1 to 4 carbon atoms (C1). Alkylene-O- of 4) is preferable.
- the alkyleneoxy group may be substituted on two different atoms (for example, a carbon atom) at the same time, or may be substituted on the same atom (for example, a carbon atom) to form a spiro ring.
- halogen or halo examples include a fluorine atom, a chlorine atom, a bromine atom or an iodine atom.
- a fluorine atom and a chlorine atom can be mentioned.
- the haloalkyl refers to an alkyl substituted with 1 to 3 halogen atoms, and examples thereof include difluoromethyl, trifluoromethyl, 1-fluoromethyl, and 2-fluoroethyl.
- the haloalkoxy refers to an alkyl—O— substituted with 1 to 3 halogen atoms, and examples thereof include trifluoromethoxy.
- Hydroxyalkyl refers to an alkyl substituted with one hydroxyl group, and examples thereof include hydroxymethyl, hydroxyethyl, 2-hydroxy-1,1-dimethylethyl, 4-hydroxy-4-methyl-n-pentyl and the like. Take as an example.
- the cyanoalkyl refers to an alkyl substituted with one cyano group, and examples thereof include cyanomethyl.
- Alkoxyalkyl refers to an alkyl substituted with one alkoxy group, for example, methoxymethyl, methoxyethyl, 2-methoxy-1,1-dimethylethyl, 4-methoxy-4-methyl-n-pentyl and the like. A specific example is given.
- aryl examples include 6 to 10-membered aromatic hydrocarbon cyclic groups. Monocyclic or bicyclic aryls are preferable, and specific examples thereof include phenyl and naphthyl, and phenyl is particularly preferable.
- the aryl that may be partially hydrogenated includes both the above-mentioned aryl and the partially hydrogenated aryl, for example, a cyclic group formed by condensing a phenyl group and a cycloalkyl group, and a cyclic group. It also includes a cyclic group formed by condensing a phenyl group and a cycloalkyl group. Specific examples thereof include phenyl, naphthyl, dihydrophenyl, indanyl, dihydronaphthyl, tetrahydronaphthyl and the like.
- Heteroaryl refers to a 5- to 10-membered monocyclic or bicyclic group containing 1 to 4 heteroatoms independently selected from the group consisting of sulfur atoms, oxygen atoms, and nitrogen atoms.
- a 5- to 6-membered monocyclic heteroaryl may contain at least one nitrogen atom and may further contain a heteroatom independently selected from the group consisting of sulfur, oxygen and nitrogen atoms.
- a 5- to 6-membered monocyclic heteroaryl group containing 1 to 4 heteroatoms independently selected from the group consisting of oxygen, sulfur and nitrogen atoms.
- pyrrolyl furanyl, thienyl, imidazolyl, pyrazolyl, oxazolyl, isooxazolyl, thiazolyl, tetrazolyl, oxadiazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, thiazinyl, triazinyl, indrill, isoindrill, benzoimidazolyl and the like.
- the aliphatic heterocycle refers to a 4- to 8-membered saturated cyclic group containing 1 to 3 heterocyclic atoms independently selected from the group consisting of an oxygen atom, a sulfur atom, and a nitrogen atom. Further, the aliphatic heterocycle may form a bicyclic group or a tricyclic group by cross-linking two carbon atoms constituting the ring with an alkylene group, and has a double bond in the ring. May be. Preferably, it contains at least one nitrogen atom and may further contain one heterocyclic atom selected from the group consisting of an oxygen atom, a sulfur atom and a nitrogen atom, and is a 4- to 7-membered monocyclic aliphatic heterocycle. Is.
- Another preferred example is a 5- to 6-membered monocyclic aliphatic heterocycle containing 1 to 2 heteroatoms independently selected from the group consisting of an oxygen atom, a sulfur atom, and a nitrogen atom.
- pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, 3-azabicyclo [3.1.0] -hexyl and the like are preferred.
- pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl and the like are preferable, and pyrrolidinyl, piperidinyl and morpholinyl are particularly preferable.
- tetrahydrofuranyl, tetrahydropyranyl, piperidinyl and the like are also preferable.
- the aliphatic heterocyclic carbonyl refers to a group in which a carbonyl group is bonded to the aliphatic heterocycle, and contains 1 to 3 heteroatoms independently selected from the group consisting of a sulfur atom, an oxygen atom, and a nitrogen atom.
- a 5- to 6-membered monocyclic aliphatic heterocyclic carbonyl containing at least one nitrogen atom, in which a carbonyl group is bonded to the nitrogen atom in the ring is preferable.
- the aliphatic heterocyclic sulfonyl refers to a group in which a sulfonyl group is bonded to the aliphatic heterocycle, and contains 1 to 3 heteroatoms independently selected from the group consisting of a sulfur atom, an oxygen atom, and a nitrogen atom.
- a 4- to 7-membered monocyclic aliphatic heterocycle containing at least one nitrogen atom and optionally containing one heteroatom selected from the group consisting of sulfur atoms, oxygen atoms, and nitrogen atoms-( SO 2 )- is preferable.
- a 5- to 6-membered monocyclic aliphatic heterocycle- (SO 2 )-containing at least one nitrogen atom and having a sulfonyl group bonded to the nitrogen atom is preferable.
- ring A represents an optionally substituted aryl group or an optionally substituted heteroaryl group.
- R 1 may be an substituted alkyl group, a substituted cycloalkyl group, a substituted aliphatic heterocyclic group, a substituted or partially hydrogenated group.
- R 2 represents a halogen atom, an alkyl group, or an alkoxy group;
- Ring B represents a nitrogen-containing aliphatic heterocyclic group which may partially contain a double bond.
- Ring C represents an aryl group or a heteroaryl group.
- R 3 and R 4 are independently substituted with a hydrogen atom, a halogen atom, a cyano group, an alkyl group, a haloalkyl group, a cyanoalkyl group, a hydroxyalkyl group, an alkoxyalkyl group, a carboxyl group, or one or two alkyl groups.
- R 5 is an optionally substituted alkyl group, an optionally substituted alkenyl group, an optionally substituted cycloalkyl group, an optionally substituted cycloalkenyl group, an optionally substituted aryl group, Substituted with a heteroaryl group which may be substituted, an aliphatic heterocyclic group which may be substituted, an alkoxy group which may be substituted, or one or two alkyl groups which may be substituted with a carboxyl group.
- R 6 and R 7 each independently represent a group selected from the group consisting of a hydrogen atom, a halogen atom, a cyano group, an alkyl group, a haloalkyl group, and a haloalkoxy group.
- aryl portion of the "optionally substituted aryl group" represented by ring A examples include 6 to 10-membered monocyclic or bicyclic aryls, and specific examples thereof include phenyl and naphthyl. Be done. In particular, a phenyl group is preferable.
- the heteroaryl portion of the "optionally substituted heteroaryl group" represented by ring A contains at least one nitrogen atom and is independently selected from the group consisting of an oxygen atom, a sulfur atom, and a nitrogen atom.
- a 5- to 6-membered monocyclic heteroaryl which may contain 1 to 3 different atoms is preferable. Specific examples thereof include a pyrrolyl group, a furanyl group, a thienyl group, a pyridinyl group, a pyrimidinyl group and a pyridadinyl group. Particularly preferably, it is a pyridinyl group.
- the substituent in the "optionally substituted aryl group” and the “optionally substituted heteroaryl group” represented by ring A may be 1 to 3 independently selected, respectively. , Halogen atom, alkyl group, haloalkyl group, cycloalkyl group, alkoxy group, haloalkoxy group, alkyleneoxy group. Specific examples thereof include a fluorine atom, a chlorine atom, a methyl group, an ethyl group, an i-propyl group, a trifluoromethyl group, a cyclopropyl group, a methoxy group, an ethoxy group, a trifluoromethoxy group and an ethyleneoxy group.
- the ring A is substituted with 1 or 2 groups independently selected from the group consisting of, for example, a halogen atom, an alkyl group, a haloalkyl group, a cycloalkyl group, an alkoxy group, a haloalkoxy group, and an alkyleneoxy group.
- 1 or 2 groups independently selected from the group consisting of, for example, a halogen atom, an alkyl group, a haloalkyl group, a cycloalkyl group, an alkoxy group, a haloalkoxy group, and an alkyleneoxy group.
- aryl groups examples include heteroaryl groups that may be substituted with one or two groups independently selected from the group consisting of halogen atoms and alkoxy groups.
- the aryl group may be substituted with 1 or 2 groups independently selected from the group consisting of a halogen atom, an alkyl group, a haloalkyl group, a cycloalkyl group, an alkoxy group, a haloalkoxy group, and an alkyleneoxy group.
- a heteroaryl group optionally substituted with a halogen atom or an alkoxy group.
- the aryl may be substituted with 1 or 2 groups independently selected from the group consisting of a halogen atom, an alkyl group, a haloalkyl group, a cycloalkyl group, an alkoxy group, a haloalkoxy group, and an alkyleneoxy group. It is a group, and particularly preferably an aryl group which may be substituted with an alkoxy group.
- phenyl substituted with an alkyleneoxy group among the “aryl groups substituted with an alkyleneoxy group” includes, for example, the following structure.
- the ring A may also be substituted with one or two groups independently selected from the group consisting of a halogen atom, an alkyl group, a haloalkyl group, a cycloalkyl group, an alkoxy group, a haloalkoxy group, and an alkyleneoxy group.
- Good aryl group examples thereof include a heteroaryl group which may be substituted with 1 or 2 groups independently selected from the group consisting of a halogen atom and an alkoxy group, and more specifically, a fluorine atom and a chlorine atom.
- examples thereof include a phenyl group which may be; a dihydrobenzofuranyl group; a pyridinyl group which may be substituted with a fluorine atom; a pyridinyl group which may be substituted with a methoxy group and the like.
- it is independently selected from the group consisting of a fluorine atom, a chlorine atom, a methyl group, an ethyl group, an i-propyl group, a trifluoromethyl group, a cyclopropyl group, a methoxy group, an ethoxy group, and a trifluoromethoxy group1
- a fluorine atom a chlorine atom
- a methyl group ethyl group
- an i-propyl group a trifluoromethyl group
- a cyclopropyl group a methoxy group, an ethoxy group, and a trifluoromethoxy group1
- It is a phenyl group that may be substituted with a group of 2 to 2, and more preferably a phenyl group that may be substituted with a methoxy group.
- alkyl of the "optionally substituted alkyl group” represented by R 1 t-butyl is particularly preferable.
- cycloalkyl of the "optionally substituted cycloalkyl group” represented by R 1 cyclopentyl and cyclohexyl are particularly preferable.
- the aliphatic heterocycle of the "optionally substituted aliphatic heterocyclic group” represented by R 1 is a difference of 1 to 2 independently selected from the group consisting of an oxygen atom, a sulfur atom, and a nitrogen atom.
- a 5- to 6-membered monocyclic aliphatic heterocyclic group containing a term atom is preferable.
- tetrahydrofuranyl, tetrahydropyranyl, or piperidinyl is preferable.
- the partially hydrogenated aryl of the "aryl group which may be substituted or partially hydrogenated” represented by R 1 include phenyl, naphthyl, indanyl and the like. .. Indanil is particularly preferred.
- the heteroaryl of the "optionally substituted heteroaryl group” represented by R 1 includes 1 to 4 heteroatoms independently selected from the group consisting of an oxygen atom, a sulfur atom, and a nitrogen atom. A 5- to 6-membered monocyclic heteroaryl group is preferred.
- a 5- to 6-membered monocyclic nitrogen-containing heteroaryl that contains at least one nitrogen atom and may further contain one heteroatom selected from the group consisting of an oxygen atom, a sulfur atom, and a nitrogen atom is preferable. .. Specific examples thereof include pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isooxazolyl, thiazolyl, oxadiazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridadinyl, thiazinyl, triazinyl and the like. Particularly preferred are pyridinyl, pyridadinyl, pyrimidinyl and the like.
- R 1 which may be substituted alkyl group "," optionally substituted cycloalkyl group ",” optionally substituted aliphatic heterocyclic group “,” may be substituted
- the substituents of the "partially hydrogenated aryl group”, “optionally substituted heteroaryl group”, and “optionally substituted carbamoyl group” are the same or different, 1-3.
- Group preferably 1-2 groups, halogen atom; hydroxyl group; oxo group; cyano group; alkyl group; hydroxyalkyl group; alkoxyalkyl group; haloalkyl group; cycloalkyl group; alkoxy group; alkanoyl group; Alkylsulfonyl group; aliphatic heterocyclic group; aliphatic heterocyclic carbonyl group which may be substituted with 1 or 2 groups independently selected from the group consisting of a halogen atom, an alkyl group, a haloalkyl group, and an alkoxyalkyl group.
- Examples include an aliphatic heterocyclic sulfonyl group; a carbamoyl group optionally substituted with 1 to 2 alkyl groups; an alkyleneoxy group and the like.
- halogen atoms hydroxyl groups; oxo groups; cyano groups; alkyl groups; hydroxyalkyl groups; alkoxyalkyl groups; haloalkyl groups; cycloalkyl groups; alkoxy groups; alkanoyl groups; alkylsulfonyl groups; aliphatic heterocyclic groups
- the aliphatic heterocyclic group is a 4- to 7-membered monocyclic aliphatic heterocyclic group containing 1 to 2 different term atoms independently selected from the group consisting of oxygen atom, sulfur atom, and nitrogen atom.
- An aliphatic heterocyclic carbonyl group which may be substituted with 1 or 2 groups independently selected from the group consisting of a halogen atom, an alkyl group, a haloalkyl group, and an alkoxyalkyl group (here, an aliphatic complex).
- the ring is a 4- to 7-membered monocyclic aliphatic heterocycle containing at least one nitrogen atom and may further contain one heteroatom selected from the group consisting of an oxygen atom, a sulfur atom and a nitrogen atom.
- Alkyl heterocyclic sulfonyl group (here, the aliphatic heterocycle contains at least one nitrogen atom and further contains one heterogeneous atom selected from the group consisting of an oxygen atom, a sulfur atom, and a nitrogen atom. It is also a 4- to 7-membered monocyclic aliphatic heterocycle); a carbamoyl group which may be substituted with 1 to 2 alkyl groups; an alkyleneoxy group and the like.
- cycloalkyl group substituted with an alkyleneoxy group includes a group in which an alkyleneoxy group is bonded to any same carbon atom on the cycloalkyl group (that is, a spiro ring), for example, trimethylene.
- the cyclohexyl group substituted with an oxy group (propyleneoxy group) includes the group of the following formula.
- a halogen atom a hydroxyl group; a cycloalkyl group; an alkoxy group; an aliphatic heterocyclic group (here, the aliphatic heterocyclic group contains at least one oxygen atom, and further contains an oxygen atom, a sulfur atom, and a nitrogen atom. It is a 4- to 7-membered monocyclic aliphatic heterocyclic group that may contain one heteroatom selected from the group consisting of a halogen atom, an alkyl group, a haloalkyl group, and an alkoxyalkyl group.
- An aliphatic heterocyclic carbonyl group which may be substituted with one or two groups selected more independently (here, the aliphatic heterocycle contains at least one nitrogen atom, and further contains an oxygen atom, a sulfur atom, and nitrogen.
- a 4- to 7-membered monocyclic aliphatic heterocycle which may contain one heteroatom selected from the group consisting of atoms); aliphatic heterocyclic sulfonyl group (here, the aliphatic heterocycle is at least It is a 4- to 7-membered monocyclic aliphatic heterocyclic group containing 1 nitrogen atom and may further contain 1 heteroatom selected from the group consisting of an oxygen atom, a sulfur atom and a nitrogen atom).
- 1-2 groups independently selected from the group consisting of carbamoyl groups optionally substituted with 1-2 alkyl groups. More specifically, it is substituted with a group selected from the group consisting of a fluorine atom; a hydroxyl group; a cyclopropyl group; a cyclobutyl group; a methoxy group; a tetrahydropyranyl group; a fluorine atom, a methyl group, a trifluoromethyl group, and a methoxymethyl group.
- Pyrrolidinylcarbonyl group which may be; piperidinylcarbonyl group which may be substituted with 1 or 2 fluorine atoms; morpholinylcarbonyl group; pyrrolidinylsulfonyl group; dimethylcarbamoyl group and the like.
- Examples of the “optionally substituted alkyl group” represented by R 1 include a methyl group, an ethyl group, an i-propyl group, an i-amyl group (3-methyl-n-butyl group), and 3-methyl-n.
- the substituent of the "optionally substituted cycloalkyl group" represented by R 1 may be the same or different 1 to 3 groups, halogen atom, hydroxyl group, oxo group, a cyano group, an alkyl group, Examples thereof include an alkoxy group, an alkoxyalkyl group and an alkyleneoxy group.
- the alkyleneoxy group may be a substituent on the same carbon of cycloalkyl. More specifically, the substituent includes 1 or 2 groups independently selected from the group consisting of a halogen atom, a hydroxyl group, an oxo group, a cyano group, an alkyl group, an alkoxy group, an alkoxyalkyl group, and an alkyleneoxy group.
- a fluorine atom is independent from the group consisting of a fluorine atom, a hydroxyl group, an oxo group, a cyano group, a methyl group, a methoxy group, an ethoxy group, an isopropoxy group, a methoxymethyl group, and a trimethyleneoxy group (propyleneoxy group). It is one or two groups selected by. In particular, a methoxy group, an ethoxy group, and a cyano group are preferable.
- the "optionally substituted cycloalkyl group" represented by R 1 is independent of the group consisting of a halogen atom, a hydroxyl group, an oxo group, a cyano group, an alkyl group, an alkoxy group, an alkoxyalkyl group, and an alkyleneoxy group. Included are cycloalkyl groups that may be substituted with one or two groups selected thereafter. More specifically, even if it is substituted with 1 to 3 groups independently selected from the group consisting of a halogen atom, a hydroxyl group, an oxo group, a cyano group, an alkyl group, an alkoxy group, an alkoxyalkyl group, and an alkyleneoxy group.
- Examples thereof include a good 3- to 7-membered monocyclic cycloalkyl group and an adamantyl group which may be substituted with a hydroxyl group. More specifically, it is independently selected from the group consisting of a cyclopropyl group; a cyclobutyl group; a fluorine atom, a hydroxyl group, an oxo group, a cyano group, a methyl group, a methoxy group, an ethoxy group, an i-propoxy group, and a methoxymethyl group.
- Cyclopentyl group optionally substituted with 1 to 3 groups; fluorine atom, hydroxyl group, oxo group, cyano group, methyl group, methoxy group, ethoxy group, i-propoxy group, and trimethyleneoxy group (propyleneoxy group).
- ) May be substituted with 1 to 3 groups independently selected from the group consisting of cyclohexyl group; cycloheptyl group and the like.
- a cyclopentyl group which may be substituted with one group selected from the group consisting of methoxy group, ethoxy group, and cyano group; substituted with one group selected from the group consisting of methoxy group, ethoxy group, and cyano group.
- a cyclohexyl group which may be used is preferable.
- Examples of the substituent of the "optionally substituted aliphatic heterocyclic group" represented by R 1 include an alkyl group, a hydroxyalkyl group, a haloalkyl group, an alkanoyl group, an alkylsulfonyl group and the like. More specifically, it is a methyl group, a hydroxymethyl group, a 2-fluoro-1-fluoromethyl-ethyl group, an acetyl group, an ethylcarbonyl group, an ethylsulfonyl group and the like.
- R 1 Represented by R 1 as "optionally substituted aliphatic heterocyclic group", the alkyl group, hydroxy group, or hydroxyalkyl group may be substituted, a tetrahydrofuranyl group; a hydroxyl group, an alkyl group, or Examples thereof include a tetrahydropyranyl group which may be substituted with a hydroxyalkyl group; a piperidinyl group which may be substituted with a group selected from the group consisting of a haloalkyl group, an alkanoyl group, and an alkylsulfonyl group.
- a tetrahydrofuranyl group a methyl group, or a tetrahydropyranyl group optionally substituted with a hydroxymethyl group; a 1-fluoromethyl-2-fluoroethyl group, an acetyl group, an ethylcarbonyl group, and an ethyl.
- Examples thereof include a piperidinyl group which may be substituted with a group selected from the group consisting of a sulfonyl group, and a tetrahydropyranyl group is preferable.
- R 1 As “optionally substituted well partially an aryl group which may be hydrogenated” represented by R 1, indanyl group (especially, 1-indanyl group, a 2-indanyl group).
- Examples of the substituent of the "optionally substituted heteroaryl group" represented by R 1 may be the same or different 1 to 3 groups, include a cyano group, an alkyl group, an alkoxy group, such as a carbamoyl group Be done. More specifically, it is a cyano group, a methyl group, a methoxy group, a carbamoyl group and the like. In particular, a methyl group is preferable.
- a pyridinyl group which may be substituted with 1 or 2 groups independently selected from the group consisting of a cyano group, an alkyl group, and an alkoxy group; a pyrimidinyl group which may be substituted with an alkyl group and the like can be mentioned.
- a pyridazinyl group which may be substituted with one group selected from the group consisting of a cyano group, a methyl group, a methoxy group, and a carbamoyl group; from the group consisting of a cyano group, a methyl group, and a methoxy group.
- Pyridynyl groups which may be substituted with 1 or 2 independently selected groups; pyrimidinyl groups which may be substituted with a methyl group and the like, and in particular, pyrimidinyl groups which may be substituted with a methyl group, and A pyridinyl group substituted with a methyl group is preferred.
- Examples of the substituent of the "optionally substituted carbamoyl group" represented by R 1 include an alkyl group. More specifically, a methyl group, an ethyl group, an i-propyl group and the like can be mentioned, and a methyl group is particularly preferable.
- Examples of the "optionally substituted carbamoyl group" represented by R 1 include a carbamoyl group, a monomethylcarbamoyl group, a dimethylcarbamoyl group and the like, and a carbamoyl group and a monomethylcarbamoyl group are preferable.
- a cycloalkyl group which may be substituted or an aliphatic heterocyclic group which may be substituted is preferable. More specifically, a 3- to 7-membered monocyclic cycloalkyl group optionally substituted with a cyano group or an alkoxy group; an aliphatic heterocycle optionally substituted with an alkyl group, a haloalkyl group, or a hydroxyalkyl group.
- a group (here, the aliphatic heterocyclic group is a group selected from the group consisting of a tetrahydrofuranyl group, a tetrahydropyranyl group, a pyrrolidinyl group, and a piperidinyl group) is preferable. Specifically, it is substituted with a cyclopentyl group; a cyclohexyl group optionally substituted with a methoxy group, an ethoxy group, or a cyano group; a piperidinyl group optionally substituted with a haloalkyl group; or an alkyl group or a hydroxyalkyl group.
- a tetrahydropyranyl group which may be present is preferable.
- a cycloalkyl group which may be substituted is particularly preferable. More specifically, a cycloalkyl group which may be substituted with a cyano group or an alkoxy group is preferable. Specifically, a cyclopentyl group; or a cyclohexyl group which may be substituted with a group selected from the group consisting of a methoxy group, an ethoxy group, and a cyano group is preferable.
- alkyl of "alkyl group” represented by R 2 the alkyl preferably a C1 ⁇ 3, specifically, methyl, ethyl, etc. i- propyl are preferable.
- alkoxy "alkoxy group" represented by R 2 is a C1 ⁇ 4 alkoxy preferably, specifically methoxy, ethoxy, i- propoxy, n- butoxy.
- R 2 include a halogen atom, an alkyl group and an alkoxy group, and a halogen atom and an alkoxy group are more preferable. Fluorine atoms or methoxy groups are particularly preferred.
- the "nitrogen-containing aliphatic heterocyclic group which may partially contain a double bond" represented by ring B contains a nitrogen atom and may further contain an oxygen atom or a sulfur atom 4 to 8.
- a member monocyclic or bicyclic aliphatic heterocycle is preferable.
- azetidinyl group, pyrrolidinyl group, imidazolinyl group, thiazolidinyl group, isothiazolidinyl group, piperidinyl group, piperazinyl group, morpholinyl group, thiomorpholinyl group, tetrahydropyridinyl group, homopiperazinyl group, homomorpholinyl group, 3-azabicyclo [3.1.0] -Hexyl group, octahydropyrrolo [3,4-c] pyrrolyl group and the like can be mentioned.
- Preferred examples thereof include an azetidinyl group, a pyrrolidinyl group, a piperidinyl group, a tetrahydropyridinyl group, a piperazinyl group, a homopiperazinyl group, an octahydropyrrolo [3,4-c] pyrrolyl group and the like.
- Further preferred examples include pyrrolidinyl groups, piperidinyl groups and the like, with pyrrolidinyl being particularly preferred.
- aryl group represented by ring C examples include monocyclic or bicyclic aryl, specifically, phenyl or naphthyl, and phenyl is preferable.
- the "heteroaryl group” represented by ring C is a 5- to 6-membered monocyclic hetero containing 1 to 4 heteroatoms independently selected from the group consisting of an oxygen atom, a sulfur atom, and a nitrogen atom.
- Aryl is mentioned. More specifically, pyridinyl is preferable.
- R 3 and R 4 are substituted with a hydrogen atom, a halogen atom, a cyano group, an alkyl group, a haloalkyl group, a cyanoalkyl group, a hydroxyalkyl group, an alkoxyalkyl group, a carboxyl group, or one or two alkyl groups. Examples thereof include a good carbamoyl group and a group independently selected from the group consisting of an alkoxy group.
- examples thereof include a group independently selected from the group consisting of a dimethylcarbamoyl group and a methoxy group.
- R 3 is a halogen atom, a cyano group, an alkyl group, a haloalkyl group, a cyanoalkyl group, a hydroxyalkyl group, an alkoxyalkyl group, a carboxyl group, 1-2 alkyl carbamoyl which may be substituted with a group Is it a group selected from the group consisting of a group and an alkoxy group, and R 4 is a hydrogen atom; R 3 is an alkoxy alkyl group, and R 4 is a halogen atom, an alkyl group, or an alkoxy group.
- R 3 and R 4 halogen atoms are both R 3 and R 4 alkyl groups; examples are examples of both R 3 and R 4 being hydrogen atoms. More specifically, R 3 is a fluorine atom, cyano group, methyl group, fluoromethyl group, cyanomethyl group, hydroxymethyl group, 1-hydroxy-1-methylethyl group, methoxymethyl group, ethoxymethyl group, carboxyl group, Is it a group selected from the group consisting of a dimethylcarbamoyl group and a methoxy group, and R 4 is a hydrogen atom; R 3 is a methoxymethyl group and R 4 is a fluorine atom, a methyl group, or methoxy. Examples include whether R 3 and R 4 are both fluorine atoms; whether R 3 and R 4 are both methyl groups; and whether R 3 and R 4 are both hydrogen atoms.
- the alkyl of "substituted alkyl group” represented by R 5, ethyl, etc. n- butyl are preferred.
- Examples of the alkenyl of the "optionally substituted alkenyl group” represented by R 5, such as n- butenyl is preferred.
- the cycloalkyl of "optionally substituted cycloalkyl group” represented by R 5, cyclohexyl is preferred.
- the cycloalkenyl of the "optionally substituted cycloalkenyl group” represented by R 5, especially, cyclohexenyl are preferred.
- aryl part of "optionally substituted aryl group” represented by R 5, phenyl, naphthyl and the like, especially preferably phenyl.
- the heteroaryl moiety of the "optionally substituted heteroaryl group" represented by R 5, includes at least one nitrogen atom, further oxygen atom, a sulfur atom 1 of hetero atom or selected from a nitrogen atom,
- a 5- to 6-membered monocyclic heteroaryl which may contain the above is preferable.
- pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isooxazolyl, thiazolyl, tetrazolyl, oxadiazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridadinyl, thiazinyl, triazinyl and the like are preferable.
- pyrazolyl and oxazolyl are preferable.
- the aliphatic heterocyclic ring "optionally substituted aliphatic have heterocyclic group" represented by R 5, includes at least one nitrogen atom, further oxygen atoms, selected from the group consisting of sulfur atom, and nitrogen atom
- a 4- to 8-membered monocyclic or bicyclic aliphatic heterocycle which may contain one different atom is preferable.
- azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, 3-azabicyclo [3.1.0] hexyl group and the like are preferable.
- Particularly preferred examples include piperidinyl and the like.
- alkoxy of the "optionally substituted alkoxy group" represented by R 5 methoxy, n- propoxy, 2-methyl -n- propoxy, 3-methyl -n- butoxy are preferred.
- Carboxyl-1 may be substituted with group 2 alkyl amino group which may be substituted with group” represented by R 5, specifically, N- methyl -N-3- carboxylic -N-propylamino group and the like can be mentioned.
- carboxyl group 1 may be substituted with 1-2 amino carbamoyl group which may be substituted with an alkyl group" in R 5, preferably, and a carbamoyl group.
- R 5 the "optionally substituted alkyl group”, “optionally substituted alkenyl group”, “optionally substituted cycloalkyl group”, “optionally substituted cycloalkenyl A group, an aryl group that may be substituted, a heteroaryl group that may be substituted, an aliphatic heterocyclic group that may be substituted, and an alkoxy group that may be substituted.
- the substituent in "" may be the same or different 1 to 2 groups, and may be substituted with a hydroxyl group; an oxo group; a cyano group; a carboxyl group; an alkoxy group; an alkanoyl group; a carboxyl group; an alkoxy.
- Carbonyl group an aliphatic heterocyclic carbonyl group which may be substituted with a carboxyl group (here, the aliphatic heterocycle preferably contains at least one nitrogen atom and further comprises an oxygen atom, a sulfur atom and a nitrogen atom.
- a 4- to 7-membered monocyclic aliphatic heterocycle which may contain one heteroatom selected from the group, more preferably a 5- to 6-membered monocyclic aliphatic heterocycle); hydroxyl group, or.
- a heteroaryl group optionally substituted with an oxo group (where, the heteroaryl group preferably comprises 1 to 4 heteroatom atoms independently selected from the group consisting of an oxygen atom, a sulfur atom and a nitrogen atom).
- a 5- to 6-membered monocyclic heteroaryl group an aliphatic heterocyclic group optionally substituted with 1 to 2 oxo groups (where the aliphatic heterocyclic group is preferably an oxygen atom, It is a 4- to 7-membered monocyclic aliphatic heterocyclic group containing 1 to 2 heterocyclic atoms independently selected from the group consisting of a sulfur atom and a nitrogen atom, and more preferably a 5- to 6-membered monocyclic group.
- a carbamoyl group which may be substituted with 1 or 2 groups independently selected from the group consisting of an alkyl group and a hydroxyl group (wherein the alkyl is a hydroxyl group, an alkoxy group, Alternatively, it may be substituted with a carboxyl group); an alkylsulfonyl group; an aminosulfonyl group optionally substituted with one or two alkyl groups; an alkylsulfonylaminocarbonyl group; substituted with one or two alkyl groups.
- Aminosulfonyl aminocarbonyl group optionally; and independent from the group consisting of amino groups optionally substituted with 1-2 groups independently selected from the group consisting of an alkyl group, an alkanoyl group, and an alkylsulfonyl group. 1 or 2 groups are selected.
- the substituent includes a hydroxyl group, an oxo group, a cyano group, a methyl group, a carboxymethyl group, a methoxy group, a carboxyl group, a carbamoyl group, an N-methylcarbamoyl group, an N-ethylcarbamoyl group, and an N-.
- the R 5 (1) An alkyl group, which may be substituted with a carboxyl group, (2) An alkenyl group, which may be substituted with a carboxyl group, (3) A 3- to 7-membered monocyclic cycloalkyl group which may be substituted with a carboxyl group, (4) A 3- to 7-membered monocyclic cycloalkenyl group which may be substituted with a carboxyl group, (5) A phenyl group, which may be substituted with a carboxyl group, (6) A heteroaryl group, which may be substituted with a carboxyl group or an alkyl group which may be substituted with a carboxyl group.
- hydroxyl group is independently selected from the group consisting of a hydroxyl group; an oxo group; a cyano group; an alkyl group which may be substituted with a carboxyl group; an alkoxy group; an alkanoyl group; a carboxyl group; an alkoxycarbonyl group; an alkyl group and a hydroxyl group.
- Carbamoyl group optionally substituted with 1-2 groups (wherein the alkyl may be substituted with a hydroxyl group, an alkoxy group or a carboxyl group); alkylsulfonylaminocarbonyl group; substituted with a carboxyl group May be aliphatic heterocyclic carbonyl group; optionally substituted with 1-2 groups independently selected from the group consisting of an alkyl group, an alkanoyl group, and an alkylsulfonyl group; 1-2 oxos.
- an aliphatic heterocyclic group optionally substituted with a group; an alkylsulfonyl group; a tetrazolyl group; and an aminosulfonyl group optionally substituted with 1 or 2 alkyl groups.
- An aliphatic heterocyclic group which may be substituted with a group of 2.
- An amino group, which may be substituted with one or two alkyl groups which may be substituted with a carboxyl group, or (10) a carbamoyl group and the like may be mentioned.
- the heteroaryl group is an oxygen atom, a sulfur atom and a nitrogen. It is a 5- to 6-membered monocyclic heteroaryl group containing 1 to 4 heteroatoms independently selected from the group consisting of atoms.
- Carbamoyl group optionally substituted with 1-2 groups wherein the alkyl may be substituted with a hydroxyl group, an alkoxy group or a carboxyl group); alkylsulfonylaminocarbonyl group; substituted with a carboxyl group.
- the aliphatic heterocyclic moiety in "an aliphatic heterocyclic group which may be substituted with a group” is preferably 1 or 2 different terms independently selected from the group consisting of an oxygen atom, a sulfur atom and a nitrogen atom.
- it is an azetidinyl group, a pyrrolidinyl group, a piperidinyl group, a piperazinyl group, a morpholinyl group, a thiomorpholinyl group, and a 3-azabicyclo [3.1.0] hexyl group.
- the aliphatic heterocycle of the "aliphatic heterocyclic carbonyl group optionally substituted with a carboxyl group” preferably contains at least one nitrogen atom and further comprises an oxygen atom, a sulfur atom and a nitrogen atom. It is a 4- to 7-membered monocyclic aliphatic heterocycle which may contain one heteroatom selected from the group, and is, for example, an azetidinyl group, a pyrrolidinyl group, an imidazolinyl group, a thiazolidinyl group, an isothiazolidinyl group, and the like.
- Examples thereof include a piperidinyl group, a piperazinyl group, a morpholinyl group, a thiomorpholinyl group, a homopiperazinyl group, or a homomorpholinyl group.
- Pyrrolidinyl groups are particularly preferred.
- the aliphatic heterocyclic group of "an aliphatic heterocyclic group optionally substituted with 1 or 2 oxo groups" is preferably independent of the group consisting of an oxygen atom, a sulfur atom and a nitrogen atom.
- Examples thereof include an azolydinyl group, a piperidinyl group, a piperazinyl group, a morpholinyl group, a thiomorpholinyl group, a tetrahydropyranyl group, a homopiperazinyl group, or a homomorpholinyl group.
- a pyrrolidinyl group or an isothiazolidinyl group is particularly preferable.
- the heteroaryl group in the "alkyl group, which may be substituted with a group selected from the group consisting of a carbonyl group” is preferably 1 to independently selected from the group consisting of an oxygen atom, a sulfur atom and a nitrogen atom. It is a 5- to 6-membered monocyclic heteroaryl group containing 4 different atoms.
- Examples thereof include a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridadinyl group, a thiazinyl group, and a triazinyl group. Particularly preferred are a tetrazolyl group, an oxadiazolyl group, and an isooxazolyl group.
- R 5 is an alkyl group substituted with a carboxyl group, alkenyl group substituted with a carboxyl group, a cycloalkyl group substituted with a carboxyl group, a cycloalkenyl group substituted with a carboxyl group, a carboxyl group Aryl group substituted with, a heteroaryl group substituted with a carboxyl group, an aliphatic heterocyclic group substituted with a carboxyl group, an alkoxy group substituted with a carboxyl group, one or two alkyl substituted with a carboxyl group. Examples thereof include an amino group which may be substituted with a group, a carbamoyl group and the like. In particular, an aliphatic heterocyclic group substituted with a carboxyl group is preferable, and a piperidinyl group substituted with a carboxyl group is particularly preferable.
- alkyl group a methyl group, an ethyl group, an i-propyl group and the like are preferable examples.
- haloalkyl group a trifluoromethyl group, a difluoromethyl group and the like are preferable.
- haloalkoxy group a trifluoromethoxy group or the like is preferable.
- R 6 or R 7 hydrogen atom, fluorine atom, chlorine atom, methyl group, ethyl group, i-propyl group, trifluoromethyl group, difluoromethyl group, trifluoromethoxy group and the like are preferable.
- R 6 is a fluorine atom, a chlorine atom, a methyl group, an i-propyl group, a trifluoromethyl group, a difluoromethyl group or a trifluoromethoxy group
- R 7 is a hydrogen atom
- R 6 is a fluorine atom, a chlorine atom, a methyl group or a trifluoromethyl group
- R 7 is a hydrogen atom. It is also preferable that both R 6 and R 7 are fluorine atoms.
- ring A represents an optionally substituted aryl group or an optionally substituted heteroaryl group.
- the substituent in the optionally substituted aryl group and the optionally substituted heteroaryl group is a halogen atom, an alkyl group, a haloalkyl group, a cycloalkyl group, an alkoxy group, a haloalkoxy group, and an alkyleneoxy.
- R 1 may be an substituted alkyl group, a substituted cycloalkyl group, a substituted aliphatic heterocyclic group, a substituted or partially hydrogenated group.
- the substituent in the alkyl group which may be substituted may be substituted with a halogen atom; a hydroxyl group; an oxo group; a cyano group; a cycloalkyl group; an alkoxy group; an alkanoyl group; or one or two alkyl groups.
- a cycloalkyl group which may be substituted, an aliphatic heterocyclic group which may be substituted, an aryl group which may be substituted or partially hydrogenated, and an aryl group which may be substituted may be substituted.
- Substituents in the heteroaryl group are halogen atom; hydroxyl group; oxo group; cyano group; alkyl group; haloalkyl group; cycloalkyl group; alkoxy group; hydroxyalkyl group; alkoxyalkyl group; alkanoyl group; 1-2 alkyl groups.
- Carbamoyl group may be substituted with; aliphatic heterocyclic group; may be substituted with 1 or 2 groups independently selected from the group consisting of a halogen atom, an alkyl group, a haloalkyl group, and an alkoxyalkyl group.
- R 2 represents a halogen atom, an alkyl group, or an alkoxy group;
- Ring B represents a nitrogen-containing aliphatic heterocyclic group which may partially contain a double bond.
- Ring C represents an aryl group or a heteroaryl group.
- R 3 and R 4 are independently substituted with a hydrogen atom, a halogen atom, a cyano group, an alkyl group, a haloalkyl group, a cyanoalkyl group, a hydroxyalkyl group, an alkoxyalkyl group, a carboxyl group, or one or two alkyl groups.
- R 5 is an optionally substituted alkyl group, an optionally substituted alkenyl group, an optionally substituted cycloalkyl group, an optionally substituted cycloalkenyl group, an optionally substituted aryl group, Substituted with a heteroaryl group which may be substituted, an aliphatic heterocyclic group which may be substituted, an alkoxy group which may be substituted, or one or two alkyl groups which may be substituted with a carboxyl group.
- the substituent in the alkyl group which may be substituted is a hydroxyl group; an oxo group; a cyano group; an alkoxy group; an alkanoyl group; a carboxyl group; an alkoxycarbonyl group; and an aliphatic heterocycle which may be substituted with a carboxyl group.
- aminosulfonyl group optionally substituted with; an aminosulfonylaminocarbonyl group optionally substituted with one or two alkyl groups; an alkylsulfonylaminocarbonyl group; and an alkyl group, an alkanoyl group, and an alkylsulfonyl group.
- 1 to 2 groups independently selected from the group consisting of amino groups which may be substituted with 1 to 2 groups independently selected from the group.
- an alkenyl group which may be substituted a cycloalkyl group which may be substituted, a cycloalkenyl group which may be substituted, an aryl group which may be substituted, a heteroaryl group which may be substituted, and the like.
- the substituents in the aliphatic heterocyclic group optionally substituted and the alkoxy group optionally substituted are a hydroxyl group; an oxo group; a cyano group; an alkyl group optionally substituted with a carboxyl group; an alkoxy group; an alkanoyl.
- the aliphatic heterocyclic group which may be used; an alkyl group (the alkyl moiety may be substituted with a hydroxyl group, an alkoxy group, or a carboxyl group), and 1 to 2 independently selected from the group consisting of a hydroxyl group.
- R 6 and R 7 each independently represent a group selected from the group consisting of a hydrogen atom, a halogen atom, a cyano group, an alkyl group, a haloalkyl group, and a haloalkoxy group.
- a preferred embodiment of the compound of the general formula [I] is a phenyl group in which the ring A may be substituted with an alkoxy group in the general formula [I].
- R 1 is a 5- to 6-membered monocyclic cycloalkyl group optionally substituted with a group selected from the group consisting of an alkoxy group and a cyano group.
- R 2 is a halogen atom or an alkoxy group
- Ring B is a pyrrolidinyl group
- R 3 is an alkoxyalkyl group
- R 4 is a hydrogen atom or a halogen atom.
- Ring C is a phenyl group
- R 5 is a piperidinyl group substituted with a carboxyl group.
- R 6 is a halogen atom or a haloalkyl group, Includes a compound in which R 7 is a hydrogen atom, or a pharmaceutically acceptable salt or cocrystal thereof.
- the compound of the general formula [I] When the compound of the general formula [I] has an asymmetric carbon atom in the molecule, it may exist as a plurality of stereoisomers (that is, diastereomeric isomers, optical isomers) based on the asymmetric carbon atom. , In the present invention, any one of these stereoisomers or a mixture thereof is included.
- the compound of the general formula [I] may be represented using the bonds shown by the following wavy lines to indicate that it is a mixture of a plurality of stereoisomers. Further, the compound of the general formula [I] may contain cis- and trans-isomers as geometric isomers, and may further contain isomers based on axial asymmetry when having axial asymmetry in the molecule. , Any one of these isomers or a mixture thereof.
- the compounds of the general formula [I] is an isotope (e.g., 3 H, 13 C, 14 C, 15 N, 18 F, 32 P, 35 S, 125 I etc.) compounds labeled with like and deuterium converter Including.
- isotope e.g., 3 H, 13 C, 14 C, 15 N, 18 F, 32 P, 35 S, 125 I etc.
- Patent Document 7 The compound of the general formula [I] or a pharmaceutically acceptable salt or cocrystal thereof is described in Patent Document 7, and can be produced by the method described in Patent Document 7.
- the compound of general formula [I] or a pharmaceutically acceptable salt or cocrystal thereof has excellent MC1R agonist activity, thereby promoting melanin production mainly in melanin-producing cells even in vivo, and in the skin. Promotes pigmentation. Therefore, a drug containing a compound of the general formula [I] or a pharmaceutically acceptable salt or co-crystal thereof as an active ingredient is expected to be improved mainly by promoting melanin production through activation of MC1R. For example, it is useful for treating or preventing photoinduced skin diseases (also called photosensitivity), hypopigmenting diseases, and side effects of phototherapy.
- photoinduced skin diseases also called photosensitivity
- hypopigmenting diseases also called side effects of phototherapy.
- Photoallergic skin diseases include photoallergic dermatitis, hydroa vacciniforme, DNA repair disorders, and porphyria (excluding protoporphyria). Examples of photoallergic dermatitis include sun urticaria, polymorphic sun rash, chronic photodermatitis, photoallergic contact dermatitis, photoallergic photosensitivity type drug eruption and the like.
- Examples of DNA repair disorders include xeroderma pigmentosum, Bloom syndrome, Werner syndrome, Rothmund-Thomson syndrome, trichothiodystrophy hair growth disorder, and UV hypersensitivity syndrome.
- Examples of porphyria include congenital myeloid porphyria, atypical porphyria, acute intermittent porphyria, porphyria cutanea, and hereditary coproporphyria.
- hypochromic diseases include ocular skin vitiligo, mottled disease, depigmented vitiligo, hypopigmentation (Ito vitiligo), phenylketonuria, nodular sclerosis, hereditary contralateral pigmentation disorder, and Waardenburg syndrome.
- Congenital hypopigmentation disorders such as Burg Syndrome, Hermannsky-Pudrac Syndrome, Chediak-East Syndrome, Glyceri Syndrome, Teats Syndrome, and Sutton Vitiligo, Vogt-Koyanagi-Harada Disease, Senile Vitiligo, Post-Bath White Spot, Plum Toxicity Acquired hypopigmenting diseases such as vitiligo can be mentioned.
- phototherapy is used for the treatment of inflammatory skin diseases, leukoplakia, circular alopecia, etc., and narrow band UVB therapy, excimalite therapy, PUVA therapy, etc. are known, but as side effects, they are short-term.
- photosensitivity symptoms and phototoxic symptoms such as redness, sunburn, and burning of the irradiated part
- long-term ones include cancer such as skin cancer and photoaging of spots and wrinkles.
- the compound of the general formula [I] or a pharmaceutically acceptable salt or cocrystal thereof can protect the skin and exert a preventive effect or a therapeutic effect.
- the compound of the general formula [I] or a pharmaceutically acceptable salt or cocrystal thereof can promote melanin production in the melanocytes present in the hair bulb, whereby the produced melanin is adjacent to the hair matrix cell. It can blacken hair by being taken in by melanin, and is also effective in preventing and improving gray hair.
- the compound of the general formula [I] or a pharmaceutically acceptable salt or cocrystal thereof has an excellent MC1R agonistic activity, and thus maintains homeostasis against external stimuli, anti-inflammatory action, and tissue fibrosis in addition to melanin production.
- MC1R agonistic activity a pharmaceutically acceptable salt or cocrystal thereof.
- Various effects such as inhibitory action are expected.
- Xeroderma pigmentosum which is a photosensitivity DNA repair disorder, is described in in vitro tests, for example, in the irregular DNA synthesis test after UV irradiation and the UV lethal susceptibility test (colony formation method) reported by Moriwaki et al. ) Etc.
- the compounds of the general formula [I] can be used for pharmaceutical purposes either in free form or in their pharmaceutically acceptable salt or co-crystal form.
- the compound of the general formula [I] or a pharmaceutically acceptable salt or cocrystal thereof contains any of an intramolecular salt, an adduct, a solvate or hydrate thereof, a polymorph of crystals, and the like.
- Pharmaceutically acceptable salts, co-crystals, intramolecular salts, additives and the like include, for example, inorganic acids such as hydrochloric acid, sulfuric acid, phosphoric acid or hydrobromic acid, acetic acid, fumaric acid, oxalic acid, citric acid, etc. Examples thereof include those containing an organic acid such as methanesulfonic acid, benzenesulfonic acid, tosylic acid or maleic acid.
- the co-crystal of the compound of the general formula [I] can be preferably used.
- a co-crystal of compound A and phosphoric acid can be obtained according to the method described in Patent Document 8.
- One or more of the compound of the general formula [I] or a pharmaceutically acceptable salt or cocrystal thereof may be administered to the patient as it is, but the compound of the general formula [I] or the pharmaceutical thereof is preferable.
- a pharmaceutically acceptable salt or cocrystal may be mixed with a medically and pharmaceutically acceptable additive and provided as a formulation in a form well known to those skilled in the art.
- Medically and pharmaceutically acceptable additives include suitable excipients, disintegrants, binders, lubricants, coatings, dyes, diluents, bases, commonly used in the manufacture of pharmaceuticals. And an isotonic agent or the like can be used.
- excipients include glucose, lactose, D-mannitol, starch, crystalline cellulose, etc.
- disintegrants include carboxymethyl cellulose, starch, or carboxymethyl cellulose calcium
- binders include hydroxypropyl cellulose, hydroxypropyl.
- a lubricant such as magnesium stearate or talc
- Polyethylene glycol, gelatin, kaolin, glycerin, purified water, hard fat and the like can be used.
- Other suitable formulations for injection or infusion include solubilizers or solubilizers that may constitute aqueous or on-use soluble injectables such as distilled water for injection, saline, propylene glycol; glucose, sodium chloride. , D-mannitol, isotonic agents such as glycerin; pharmaceutical additives such as pH adjusters such as inorganic acids, organic acids, inorganic bases or organic bases can be used.
- the compound of the general formula [I] or a pharmaceutically acceptable salt or co-crystal thereof was prepared in an appropriate administration form (powder, injection, tablet, capsule, topical external application, etc.) together with the above-mentioned additives. Later, it can be administered to a patient (human or animal) by an appropriate administration method (for example, intravenous administration, oral administration, transdermal administration, local administration, etc.) according to the administration form. Of these, oral administration is preferred.
- Dosage should take into account age, weight, general health, gender, diet, duration of administration, method of administration, rate of excretion, drug combination, degree of medical condition of the patient being treated at the time of administration, and other factors. It is decided. Dosages of pharmaceuticals containing compounds of general formula [I] or pharmaceutically acceptable salts or co-crystals thereof are low toxicity and safe to use, with photodermic skin diseases, hypopigmenting diseases, phototherapy. The amount is not particularly limited as long as it can exert a therapeutic effect or a preventive effect on diseases and conditions such as side effects and gray hair, but for example, the amount of the compound of the general formula [I] is preferably 1 to 1000 mg / day. Is 10-500 mg / day.
- the amount of the compound of I] is preferably 50 to 500 mg / day, more preferably 80 to 400 mg / day, particularly preferably 100 to 300 mg / day, and for example, 100 mg / day, 150 mg / day, 200 mg / day, 250 mg / day. Daily, 300 mg / day or doses between these are exemplified.
- Oral administration is particularly preferable, and a drug containing the compound of the general formula [I] or a pharmaceutically acceptable salt or cocrystal thereof is orally administered in an amount of, for example, 50 to 500 mg of the compound of the general formula [I].
- / Day preferably 80-400 mg / day, more preferably 100-300 mg / day, specifically 100 mg / day, 150 mg / day, 200 mg / day, 250 mg / day, 300 mg / day, or between these.
- Administered in dose preferably 80-400 mg / day, more preferably 100-300 mg / day, specifically 100 mg / day, 150 mg / day, 200 mg / day, 250 mg / day, 300 mg / day, or between these.
- the compounds A and B used in the examples are the following compounds.
- Example 1 [Measurement of human and mouse MC1R agonist activity (cAMP measurement)] Human fetal kidney cell 293 (HEK293) cells in which human MC1R or mouse MC1R was stably expressed were used. Compound solutions of each concentration were mixed with cAMP assay buffer (HBSS (Hank's Balanced Salt Solution) containing 10 mM HEPES, 1% BSA) and dispensed into 96 well black half area plates.
- HBSS Human fetal kidney cell 293
- Human MC1R-expressing cells (3 ⁇ 10 3 cells / well) or mouse MC1R-expressing cells (18 ⁇ 10 3 cells / well) are suspended in a cAMP assay buffer containing 0.5 mM IBM X, dispensed into the above 96-well plate, and then mixed. After standing at 37 ° C for 30 minutes, the intracellular cAMP concentration was measured by the fluorescence method using Envision (ex. 320 nm, em. 665 nm and 615 nm).
- the quantitative value of cAMP concentration was calculated from the ratio value (measured value of 665 nm / measured value of 615 nm x 10000) using Prism 5.02, and ⁇ MSH, compound A and NDP- ⁇ MSH ([Nle4, D). -Phe7] - ⁇ -MSH) maximum reaction amount Emax and EC50 (concentration showing a reaction of 1/2 of Emax of ⁇ MSH) were calculated by nonlinear regression.
- Example 2 [Evaluation of binding selectivity for human MCR subtypes] The binding of compound A to MC1R, MC3R, MC4R and MC5R was assessed by a radiolabeled ligand ([125 I] NDP- ⁇ -MSH) binding assay.
- MC1R I.
- Buffer 1.
- Incubation buffer 25 mmol / L HEPES, pH 7.0, 100 mmol / L NaCl, 1 mmol / L 1,10-Phenanthroline, 1.5 mmol / L CaCl 2 , 1 mmol / L DDL 4 , one Complete TM protease inhibitor tablet / 100 mL 2.
- Wash buffer 50 mmol / L Tris-HCl, pH 7.4
- Receptor preparation Human recombinant MC1R (PerkinElmer) was dissolved in incubation buffer.
- MC3R I.
- Buffer 1.
- Incubation buffer 25 mmol / L HEPES, pH 7.0, 100 mmol / L NaCl, 1 mmol / L 1,10-Phenanthroline, 1.5 mmol / L CaCl 2 , 1 mmol / L DDL 4 , one Complete TM protease inhibitor tablet / 100 mL 2.
- Wash buffer 50 mmol / L Tris-HCl, pH 7.4
- Receptor preparation Human recombinant MC3R (PerkinElmer) was dissolved in incubation buffer.
- MC4R I. Buffer: 1. Incubation buffer: 25 mmol / L HEPES, pH 7.0, 1.5 mmol / L CaCl 2 , 1 mmol / L DDL 4 , 100 mmol / L NaCl, 1 mmol / L 1,10-Phenanthroline, one Complete TM protease inhibitor tablet / 100 mL 2. Wash buffer: 50 mmol / L Tris-HCl, pH 7.4
- Receptor preparation Human recombinant MC4R (PerkinElmer) was dissolved in incubation buffer.
- MC5R I.
- Buffer 1.
- Incubation buffer 25 mmol / L HEPES, pH 7.0, 100 mmol / L NaCl, 1 mmol / L 1,10-Phenanthroline, 1.5 mmol / L CaCl 2 , 1 mmol / L DDL 4 , one complete TM protease inhibitorior tablet / 100 mL 2.
- Wash buffer 50 mmol / L Tris-HCl, pH 7.4
- Receptor preparation Human recombinant MC5R (PerkinElmer) was dissolved in incubation buffer.
- Inhibition rate (%) ⁇ 1-(ca) / (ba) ⁇ x 100
- c Radiation dose in the presence of the test substance (individual cpm value)
- Ki IC50 / (1 + [Ligand] / Kd) [Ligand]: Radioligand concentration used in the assay Kd: For the dissociation constant of the binding of the radioligand to each receptor, refer to the historical data of Europhins Panlabs, the test site.
- Example 3 [Measurement of melanin production activity against mouse melanoma cell line] The effect of the MC1R agonist on melanin production from mouse melanoma cell lines was evaluated by the following procedure.
- B16F1 cells were used for measuring melanin production activity.
- B16F1 cells were cultured using Dulbecco's Modified Eagle Medium (DMEM) containing 10% fetal bovine serum (FBS) and 100 U / mL Penicillin-Streptomycin.
- DMEM Dulbecco's Modified Eagle Medium
- FBS fetal bovine serum
- ⁇ value AB A: Median melanin production in each concentration group of each test substance B: Median melanin production in the DMSO group
- the maximum ⁇ value of NDP- ⁇ MSH was calculated by nonlinear regression using each concentration group ⁇ value of NDP- ⁇ MSH. This maximum ⁇ value was set to 100%, and each concentration group ⁇ value of NDP- ⁇ MSH and compound A was converted into a percentage by the following formula to calculate the% value.
- Example 4 [Examination of blackening effect of mouse hair] The effect of the MC1R agonist on C57BL / 6J-Ay / a mice was evaluated by the following procedure.
- mice Male C57BL / 6JHamSlc-Ay / + mice (Japan SLC Co., Ltd.) were used. In order to use individuals with a growing hair cycle, tests were performed at 29 or 30 days of age. Before the start of administration, the back of the mouse was shaved with a hair clipper, individuals with no abnormalities on the skin such as cuts and bruises were selected, and a simulation method was performed so that the weight of each group was uniform in the group composition shown in Table 3. I divided them into groups. The administration (including preparation) of the test substance and the evaluation of the hair were shared by different experimenters, and the evaluation was blinded. The test substance was administered once a day for 6 days (day 0-day 5), with the administration start date as day 0.
- ⁇ Preparation method of test substance> Compound A: The required amount was weighed in terms of free form and suspended in a 0.5% (w / v) methylcellulose (0.5% MC) aqueous solution to the desired concentration. It was orally administered in a volume of 0.1 mL / 10 g (body weight).
- NDP- ⁇ MSH control drug: The required amount was weighed in terms of free form and dissolved in Dulbecco's phosphate-buffered saline (PBS) at a concentration of 0.4 mg / mL. It was subcutaneously administered in a volume of 0.05 mL / 10 g (body weight).
- the statistical analysis method was performed using SAS, and the significance level was set to 0.05.
- the 0.5% MC administration group and the NDP- ⁇ MSH group were analyzed by Fisher's direct probability method.
- the comparison between the 0.5% MC-administered group and each compound A-administered group was analyzed by Fisher's direct probability method (fixed-order test). As a fixed-order test, Fisher's direct probability method was performed from the high dose, and if significant, the lower dose was analyzed in the same manner.
- the MC1R agonist was significantly blackened after shaving at a dose of 0.3 mg / kg or 3 mg / kg (Table 4).
- Example 5 Skin melanin-related gene expression in a clinical trial of compound A in healthy individuals
- compound A was given a single oral dose. It was administered.
- Subjects were assigned to 8 cases of placebo and 6 cases to each dose of 30, 100, 300, 600 mg of compound A.
- Subjects had a biopsy punch to collect a small piece of back skin tissue the day before and one day after administration of the drug.
- Human skin tissue mRNA expression intensity was measured using Affymetrix's GeneChip Human Gene 2.0 ST Array System (Catalog No. 902112) with reference to the kit instructions.
- tyrosinase-related protein 1 TYRP1
- PMEL premelanosomal protein
- Example 6 Changes in skin melanin density in a clinical trial of compound A in healthy subjects
- compound A was orally repeated once daily for 14 days. It was administered.
- Subjects were assigned to 12 placebo patients and 9 patients at doses of 30, 150, 300, and 450 mg of compound A.
- the skin color of the subject before dosing was determined by the Fitzpatrick skin classification, type III to V in the placebo group, type II to IV in the 30 to 300 mg group of compound A, and type V in the 450 mg group. was.
- the skin melanin density was measured using a Konica Minolta spectrophotometer (model number CM-600d) with reference to the product manual.
- Example 7 Ultraviolet A irradiation mouse photoaging model ⁇ Test animals and test design> Male albino hairless mice (strain name Hos: HR-1, Hoshino Test Animal Breeding Center Co., Ltd.) were used. The mice in each group were divided into groups so that the weights of the mice were uniform, and from the next day, the groups other than the untreated group were gradually irradiated with ultraviolet A A for 8 weeks at a frequency of 5 times a week to skin the skin. Caused photoaging. The UV A irradiation schedule was based on the report by Minami et al. (J Nutrition Biochem 2009, 20, 389).
- Compound B The required amount was weighed in terms of free form and suspended in 0.5% MC to the desired concentration. It was orally administered at a volume of 0.1 mL / 10 g (body weight) once a day for 8 weeks at 3 mg / kg.
- HP-228 control drug, melanocortin agonist peptide
- ⁇ Evaluation items> Evaluation of skin wrinkles by macroscopic observation (evaluation item a): The state of skin wrinkles is evaluated from 0 (fine wrinkles) to 3 (deep and coarse wrinkles) once a week for 8 weeks after UV A irradiation. It was evaluated on a four-point scale. Quantification of type I collagen content in skin (evaluation item b): Mice were euthanized 8 weeks after UV A irradiation, and the back skin was removed. Acetic acid and pepsin were added to the collected skin to prepare a homogenate. The amount of collagen in the skin homogenate reduced by ultraviolet A was measured using the Mouse Collagen Type I ELISA Kit.
- Skin histological examination (evaluation item c): Paraffin sections were prepared after fixing the collected skin with 10% neutral buffered formalin. An enzyme antibody method immunostaining method using an anti-cyclobutane-type pyrimidine dimer (CPD) antibody (Cosmo Bio Co., Ltd.) detected UV A-induced DNA damage.
- CPD anti-cyclobutane-type pyrimidine dimer
- the skin wrinkle score was measured by Mann-Whitney U test with adjusted multiplicity, and the significance level was 0.05.
- the significance test for the amount of collagen was performed by t-test or Dunnett's multiple comparison test, and the significance level was set to 0.05.
- the result of the evaluation item a is shown in FIG.
- the result of the evaluation item b is shown in FIG.
- the amount of type I collagen in the skin of the solvent control group was decomposed by ultraviolet A irradiation and significantly decreased as compared with the untreated group.
- CPD is a UV-induced DNA damage marker
- UV A irradiation increased the degree of positivity in the skin.
- the epidermal CPD staining of the compound B-administered group and the HP-228-administered group tended to be less positive than that of the solvent control group. From the above, it was shown that Compound B may exert effects other than the melanin-producing action to treat or prevent actinic skin diseases.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
上記の通り、MCRのリガンドであるα-メラノサイト刺激ホルモン(α-MSH)のアナログが光線性皮膚疾患等の治療剤として開発されている(特許文献1~6)が、MC1Rの選択的アゴニストではなく、副作用の発現が懸念される。また、ペプチドであるため経口投与が出来ず、医療従事者による定期的な皮下インプラントが必要であることから利便性に課題を持つと考えられる。
そのため、より安全かつ患者の負担なく効果的に治療が可能な光線性皮膚疾患等の治療又は予防用医薬組成物が求められている。
本発明は、下記一般式[I]で表される化合物もしくはその医薬的に許容しうる塩又は共結晶の有効量を治療又は予防を必要とする対象に投与する工程を含む、主にメラニン産生を促進することにより治療又は予防しうる状態(プロトポルフィリン症または白斑症(尋常性白斑)を除く)を治療又は予防するための方法を提供する。
本発明は、主にメラニン産生を促進することにより治療又は予防しうる状態(プロトポルフィリン症または白斑症(尋常性白斑)を除く)を治療又は予防するための、下記一般式[I]で表される化合物もしくはその医薬的に許容しうる塩又は共結晶を提供する。
本発明は、下記一般式[I]で表される化合物もしくはその医薬的に許容しうる塩又は共結晶の、主にメラニン産生を促進することにより治療又は予防しうる状態(プロトポルフィリン症または白斑症(尋常性白斑)を除く)を治療又は予防するための医薬の製造における使用を提供する。
ここで、一般式[I]で表される化合物は1-{2-[(3S,4R)-1-{[(3R,4R)-1-シクロペンチル-3-フルオロ-4-(4-メトキシフェニル)ピロリジン-3-イル]カルボニル}-4-(メトキシメチル)ピロリジン-3-イル]-5-(トリフルオロメチル)フェニル}ピペリジン-4-カルボン酸もしくはその医薬的に許容しうる塩又は共結晶(以下、化合物Aともいう。)が好ましい。
また、メラニン産生を促進することにより治療又は予防しうる状態としては、光線性皮膚疾患(プロトポルフィリン症を除く)、低色素性疾患(白斑症(尋常性白斑)を除く)、光線療法の副作用、白髪などが挙げられ、光線性皮膚疾患としては、光アレルギー性皮膚炎、種痘様水疱症、DNA修復異常症、ポルフィリン症(プロトポルフィリン症を除く)が挙げられる。ここで、光アレルギー性皮膚炎としては日光蕁麻疹、多形日光疹、慢性光線性皮膚炎、光アレルギー性接触皮膚炎、光アレルギー性光線過敏症型薬疹等が挙げられ、DNA修復異常症としては色素性乾皮症、コケーン症候群、ブルーム症候群、ウェルナー症候群、ロスムンド・トムソン症候群、硫黄欠乏性毛髪発育異常症、紫外線高感受性症候群等が挙げられ、ポルフィリン症(プロトポルフィリン症を除く)としては先天性骨髄性ポルフィリン症、異型ポルフィリン症、急性間欠性ポルフィリン症、晩発性皮膚ポルフィリン症、遺伝性コプロポルフィリン症等が挙げられる。特に、日光蕁麻疹、多形日光疹などの光アレルギー性皮膚炎、先天性骨髄性ポルフィリン症、異型ポルフィリン症、急性間欠性ポルフィリン症、晩発性皮膚ポルフィリン症、遺伝性コプロポルフィリン症などのポルフィリン症(プロトポルフィリン症を除く)、色素性乾皮症などのDNA修復異常症などが好ましい。また、低色素性疾患(白斑症(尋常性白斑)を除く)としては、眼皮膚白皮症、まだら症、脱色素性母斑、低色素症(伊藤白斑)、フェニルケトン尿症、結節性硬化症、遺伝性対側性色素異常症、ワールデンブルグ症候群、ヘルマンスキー・プドラック症候群、チェディアックー東症候群、グリセリ症候群、ティーツ症候群などの先天性低色素性疾患、およびサットン白斑、フォークト-小柳-原田病、老人性白斑、海水浴後白斑、梅毒性白斑などの後天性低色素性疾患が挙げられる。
また、一般式[I]で表される化合物もしくはその医薬的に許容しうる塩又は共結晶の投与量が50~500mg/日であることが好ましく、100~300mg/日であることがより好ましい。
<置換基の定義>
本明細書における各基の定義は、特に明記しない限り、自由に組み合わせることができる。
本明細書において、アルキルとは、炭素数1~6(C1~6)の直鎖又は分岐鎖状の飽和炭化水素鎖基をいう。とりわけ炭素数1~4(C1~4)の基が好ましい。具体的には、メチル、エチル、n-プロピル、i-プロピル、n-ブチル、t-ブチル、2-メチル-n-ブチル、i-アミル(3-メチル-n-ブチル)、2-メチル-n-ペンチルなどが挙げられる。とりわけ、メチル、エチル、i-プロピル、又はt-ブチルが好ましい。
アルケニルとは、少なくとも1の二重結合を有する炭素数2~6(C2~6)の直鎖又は分岐鎖状の炭化水素鎖基をいう。とりわけ、炭素数2~4(C2~4)の基が挙げられる。具体的には、ビニル、プロペニル、ブテニルなどが挙げられる。
シクロアルケニルとは、少なくとも1の二重結合を有する炭素数3~7(C3~7)の環状基をいう。具体的には、シクロプロペニル、シクロブテニル、シクロペンテニル、シクロヘキセニルなどが挙げられる。
アルカノイルとは、前記のアルキルにカルボニル(C=O)が結合した基をいい、炭素数1~6(C1~6)の直鎖又は分岐鎖状のアルキル-C(=O)-が挙げられ、炭素数1~4(C1~4)のアルキル-C(=O)-が好ましい。具体的には、アセチル、プロピオニル、ブチリル等が挙げられる。
アルキレンオキシとは、前記のアルキレンに酸素原子が結合した2価基をいい、具体的には炭素数1~6(C1~6)のアルキレン-O-が挙げられ、炭素数1~4(C1~4)のアルキレン-O-が好ましい。アルキレンオキシ基は異なる2つの原子(例えば、炭素原子)上に同時に置換していてもよく、同一原子(例えば、炭素原子)上に置換してスピロ環形成していてもよい。
ハロアルキルとは、1~3個のハロゲン原子で置換されたアルキルをいい、例えば、ジフルオロメチル、トリフルオロメチル、1-フルオロメチル、2-フルオロエチルなどが具体例として挙げられる。
ハロアルコキシとは、1~3個のハロゲン原子で置換されたアルキル-O-をいい、例えば、トリフルオロメトキシなどが具体例として挙げられる。
シアノアルキルとは、1個のシアノ基で置換されたアルキルをいい、例えば、シアノメチルなどが具体例として挙げられる。
アルコキシアルキルとは、1個のアルコキシ基で置換されたアルキルをいい、例えば、メトキシメチル、メトキシエチル、2-メトキシ-1,1-ジメチルエチル、4-メトキシ-4-メチル-n-ペンチルなどが具体例として挙げられる。
部分的に水素化されていてもよいアリールとは、前記のアリール及び前記アリールが部分的に水素化されたものの両者を含み、例えばフェニル基とシクロアルキル基が縮合して形成する環状基、及びフェニル基とシクロアルケニル基が縮合して形成する環状基なども含まれる。具体的には、フェニル、ナフチル、ジヒドロフェニル、インダニル、ジヒドロナフチル、テトラヒドロナフチルなどが挙げられる。
一般式[I]における、各記号について、以下に説明する。
式中、環Aは置換されていてもよいアリール基、又は置換されていてもよいヘテロアリール基を表し、
R1は置換されていてもよいアルキル基、置換されていてもよいシクロアルキル基、置換されていてもよい脂肪族複素環基、置換されていてもよく部分的に水素化されていてもよいアリール基、置換されていてもよいヘテロアリール基、又は1~2個のアルキル基で置換されていてもよいカルバモイル基を表し、
R2はハロゲン原子、アルキル基、又はアルコキシ基を表し;
環Bは、部分的に二重結合を含んでいてもよい含窒素脂肪族複素環基を表し、
環Cはアリール基、又はヘテロアリール基を表し、
R3及びR4は各々独立して、水素原子、ハロゲン原子、シアノ基、アルキル基、ハロアルキル基、シアノアルキル基、ヒドロキシアルキル基、アルコキシアルキル基、カルボキシル基、1~2個のアルキル基で置換されていてもよいカルバモイル基、及びアルコキシ基からなる群より選ばれる基を表し;
R5は置換されていてもよいアルキル基、置換されていてもよいアルケニル基、置換されていてもよいシクロアルキル基、置換されていてもよいシクロアルケニル基、置換されていてもよいアリール基、置換されていてもよいヘテロアリール基、置換されていてもよい脂肪族複素環基、置換されていてもよいアルコキシ基、カルボキシル基で置換されていてもよい1~2個のアルキル基で置換されていてもよいアミノ基、又はカルボキシル基で置換されていてもよい1~2個のアルキル基で置換されていてもよいカルバモイル基を表し、
R6及びR7は各々独立して、水素原子、ハロゲン原子、シアノ基、アルキル基、ハロアルキル基、及びハロアルコキシ基からなる群より選ばれる基を表す。
R1で表される「置換されていてもよいシクロアルキル基」のシクロアルキルとしては、とりわけ、シクロペンチル、及びシクロヘキシルが好ましい。
R1で表される「置換されていてもよい脂肪族複素環基」の脂肪族複素環としては、酸素原子、硫黄原子、及び窒素原子からなる群より独立して選ばれる1~2の異項原子を含む、5~6員単環式脂肪族複素環基が好ましい。具体的には、テトラヒドロフラニル、テトラヒドロピラニル、又はピペリジニルが好ましい。
R1で表される「置換されていてもよく部分的に水素化されていてもよいアリール基」の部分的に水素化されていてもよいアリールとしては、フェニル、ナフチル、インダニルなどが挙げられる。とりわけ、インダニルが好ましい。
R1で表される「置換されていてもよいヘテロアリール基」のヘテロアリールとしては、酸素原子、硫黄原子、及び窒素原子からなる群より独立して選ばれる1~4の異項原子を含む5~6員単環式のヘテロアリール基が好ましい。とりわけ、少なくとも1の窒素原子を含み、さらに酸素原子、硫黄原子、及び窒素原子からなる群より選ばれる1の異項原子を含んでいてもよい5~6員単環式含窒素ヘテロアリールが好ましい。具体的には、ピロリル、イミダゾリル、ピラゾリル、オキサゾリル、イソオキサゾリル、チアゾリル、オキサジアゾリル、ピリジニル、ピラジニル、ピリミジニル、ピリダジニル、チアジニル、トリアジニルなどが挙げられる。特に好ましくは、ピリジニル、ピリダジニル、ピリミジニルなどが挙げられる。
より詳細には、ハロゲン原子;水酸基;シクロアルキル基;アルコキシ基;脂肪族複素環基(ここにおいて、脂肪族複素環基は少なくとも1の酸素原子を含み、さらに酸素原子、硫黄原子、及び窒素原子からなる群より選ばれる1の異項原子を含んでいてもよい4~7員単環式の脂肪族複素環基である);ハロゲン原子、アルキル基、ハロアルキル基、及びアルコキシアルキル基からなる群より独立して選ばれる1~2の基で置換されていてもよい脂肪族複素環カルボニル基(ここにおいて、脂肪族複素環は少なくとも1の窒素原子を含み、さらに酸素原子、硫黄原子、及び窒素原子からなる群より選ばれる1の異項原子を含んでいても良い4~7員単環式の脂肪族複素環である);脂肪族複素環スルホニル基(ここにおいて、脂肪族複素環は少なくとも1の窒素原子を含み、さらに酸素原子、硫黄原子、及び窒素原子からなる群より選ばれる1の異項原子を含んでいてもよい4~7員単環式の脂肪族複素環基である);及び1~2個のアルキル基で置換されていてもよいカルバモイル基からなる群より独立して選ばれる1~2の基が挙げられる。
より具体的には、フッ素原子;水酸基;シクロプロピル基;シクロブチル基;メトキシ基;テトラヒドロピラニル基;フッ素原子、メチル基、トリフルオロメチル基、及びメトキシメチル基からなる群より選ばれる基で置換されていてもよいピロリジニルカルボニル基;1~2個のフッ素原子で置換されていてもよいピペリジニルカルボニル基;モルホリニルカルボニル基;ピロリジニルスルホニル基;ジメチルカルバモイル基などである。
当該置換基として、より詳細には、ハロゲン原子、水酸基、オキソ基、シアノ基、アルキル基、アルコキシ基、アルコキシアルキル基、及びアルキレンオキシ基からなる群より独立して選ばれる1~2の基などが挙げられる。より具体的には、フッ素原子、水酸基、オキソ基、シアノ基、メチル基、メトキシ基、エトキシ基、イソプロポキシ基、メトキシメチル基、及びトリメチレンオキシ基(プロピレンオキシ基)からなる群より独立して選ばれる1~2の基などである。とりわけ、メトキシ基、エトキシ基、及びシアノ基が好ましい。
より詳細には、ハロゲン原子、水酸基、オキソ基、シアノ基、アルキル基、アルコキシ基、アルコキシアルキル基、及びアルキレンオキシ基からなる群より独立して選ばれる1~3の基で置換されていてもよい3~7員単環式シクロアルキル基、及び水酸基で置換されていてもよいアダマンチル基などが挙げられる。
より具体的には、シクロプロピル基;シクロブチル基;フッ素原子、水酸基、オキソ基、シアノ基、メチル基、メトキシ基、エトキシ基、i-プロポキシ基、及びメトキシメチル基からなる群より独立して選ばれる1~3の基で置換されていてもよいシクロペンチル基;フッ素原子、水酸基、オキソ基、シアノ基、メチル基、メトキシ基、エトキシ基、i-プロポキシ基、及びトリメチレンオキシ基(プロピレンオキシ基)からなる群より独立して選ばれる1~3の基で置換されていてもよいシクロヘキシル基;シクロヘプチル基などが挙げられる。
とりわけ、メトキシ基、エトキシ基、及びシアノ基からなる群より選ばれる1の基で置換されていてもよいシクロペンチル基;メトキシ基、エトキシ基、及びシアノ基からなる群より選ばれる1の基で置換されていてもよいシクロヘキシル基などが好ましい。
より具体的には、テトラヒドロフラニル基;メチル基、又はヒドロキシメチル基で置換されていてもよい、テトラヒドロピラニル基;1-フルオロメチル-2-フルオロエチル基、アセチル基、エチルカルボニル基、及びエチルスルホニル基からなる群より選ばれる基で置換されていてもよい、ピペリジニル基などが挙げられ、テトラヒドロピラニル基が好ましい。
より具体的には、シアノ基、メチル基、メトキシ基、及びカルバモイル基からなる群より選ばれる1の基で置換されていてもよいピリダジニル基;シアノ基、メチル基、及びメトキシ基からなる群より独立して選ばれる1~2の基で置換されていてもよいピリジニル基;メチル基で置換されていてもよいピリミジニル基などが挙げられ、とりわけメチル基で置換されていてもよいピリミジニル基、及びメチル基で置換されたピリジニル基が好ましい。
環Cで表される「ヘテロアリール基」としては、酸素原子、硫黄原子、及び窒素原子からなる群より独立して選ばれる1~4の異項原子を含む5~6員単環式のヘテロアリールが挙げられる。より具体的にはピリジニルが好ましい。
R5で表される「置換されていてもよいアルケニル基」のアルケニルとしては、n-ブテニルなどが好ましい。
R5で表される「置換されていてもよいシクロアルキル基」のシクロアルキルとしては、シクロヘキシルが好ましい。
R5で表される「置換されていてもよいシクロアルケニル基」のシクロアルケニルとしては、とりわけ、シクロヘキセニルが好ましい。
R5で表される「カルボキシル基で置換されていてもよい1~2個のアルキル基で置換されていてもよいカルバモイル基」としては、好ましくは、カルバモイル基が挙げられる。
(1)カルボキシル基で置換されていてもよい、アルキル基、
(2)カルボキシル基で置換されていてもよい、アルケニル基、
(3)カルボキシル基で置換されていてもよい、3~7員単環式シクロアルキル基、
(4)カルボキシル基で置換されていてもよい、3~7員単環式シクロアルケニル基、
(5)カルボキシル基で置換されていてもよい、フェニル基、
(6)カルボキシル基、又はカルボキシル基で置換されていてもよいアルキル基で置換されていてもよい、ヘテロアリール基、
(7)水酸基;オキソ基;シアノ基;カルボキシル基で置換されていてもよいアルキル基;アルコキシ基;アルカノイル基;カルボキシル基;アルコキシカルボニル基;アルキル基、及び水酸基からなる群より独立して選ばれる1~2の基で置換されていてもよいカルバモイル基(ここにおいて、該アルキルは水酸基、アルコキシ基、又はカルボキシル基で置換されていてもよい);アルキルスルホニルアミノカルボニル基;カルボキシル基で置換されていてもよい脂肪族複素環カルボニル基;アルキル基、アルカノイル基、及びアルキルスルホニル基からなる群より独立して選ばれる1~2の基で置換されていてもよいアミノ基;1~2個のオキソ基で置換されていてもよい脂肪族複素環基;アルキルスルホニル基;テトラゾリル基;及び1~2個のアルキル基で置換されていてもよいアミノスルホニル基からなる群より独立して選ばれる1~2の基で置換されていてもよい、脂肪族複素環基、
(8)シアノ基;カルボキシル基;水酸基、又はオキソ基で置換されていてもよいヘテロアリール基;1~2個のアルキル基で置換されていてもよいアミノスルホニルアミノカルボニル基;及びアルキルスルホニルアミノカルボニル基からなる群より選ばれる基で置換されていてもよい、アルコキシ基、
(9)カルボキシル基で置換されていてもよい1~2個のアルキル基で置換されていてもよい、アミノ基、又は
(10)カルバモイル基などが挙げられる。
式中、環Aは置換されていてもよいアリール基、又は置換されていてもよいヘテロアリール基を表し、
ここにおいて、置換されていてもよいアリール基、及び置換されていてもよいヘテロアリール基における置換基は、ハロゲン原子、アルキル基、ハロアルキル基、シクロアルキル基、アルコキシ基、ハロアルコキシ基、及びアルキレンオキシ基からなる群より独立して選ばれる1~3の基であり;
R1は置換されていてもよいアルキル基、置換されていてもよいシクロアルキル基、置換されていてもよい脂肪族複素環基、置換されていてもよく部分的に水素化されていてもよいアリール基、置換されていてもよいヘテロアリール基、又は1~2個のアルキル基で置換されていてもよいカルバモイル基を表し、
ここにおいて、置換されていてもよいアルキル基における置換基は、ハロゲン原子;水酸基;オキソ基;シアノ基;シクロアルキル基;アルコキシ基;アルカノイル基;1~2個のアルキル基で置換されていてもよいカルバモイル基;脂肪族複素環基;ハロゲン原子、アルキル基、ハロアルキル基、及びアルコキシアルキル基からなる群より独立して選ばれる1~2の基で置換されていてもよい脂肪族複素環カルボニル基;アルキルスルホニル基;脂肪族複素環スルホニル基;及びアルキレンオキシ基からなる群より独立して選ばれる1~3の基であり、
また、置換されていてもよいシクロアルキル基、置換されていてもよい脂肪族複素環基、置換されていてもよく部分的に水素化されていてもよいアリール基、及び置換されていてもよいヘテロアリール基における置換基は、ハロゲン原子;水酸基;オキソ基;シアノ基;アルキル基;ハロアルキル基;シクロアルキル基;アルコキシ基;ヒドロキシアルキル基;アルコキシアルキル基;アルカノイル基;1~2個のアルキル基で置換されていてもよいカルバモイル基;脂肪族複素環基;ハロゲン原子、アルキル基、ハロアルキル基、及びアルコキシアルキル基からなる群より独立して選ばれる1~2の基で置換されていてもよい脂肪族複素環カルボニル基;アルキルスルホニル基;脂肪族複素環スルホニル基;及びアルキレンオキシ基からなる群より独立して選ばれる1~3の基であり;
R2はハロゲン原子、アルキル基、又はアルコキシ基を表し;
環Bは、部分的に二重結合を含んでいてもよい含窒素脂肪族複素環基を表し、
環Cはアリール基、又はヘテロアリール基を表し、
R3及びR4は各々独立して、水素原子、ハロゲン原子、シアノ基、アルキル基、ハロアルキル基、シアノアルキル基、ヒドロキシアルキル基、アルコキシアルキル基、カルボキシル基、1~2個のアルキル基で置換されていてもよいカルバモイル基、及びアルコキシ基からなる群より選ばれる基を表し;
R5は置換されていてもよいアルキル基、置換されていてもよいアルケニル基、置換されていてもよいシクロアルキル基、置換されていてもよいシクロアルケニル基、置換されていてもよいアリール基、置換されていてもよいヘテロアリール基、置換されていてもよい脂肪族複素環基、置換されていてもよいアルコキシ基、カルボキシル基で置換されていてもよい1~2個のアルキル基で置換されていてもよいアミノ基、又はカルボキシル基で置換されていてもよい1~2個のアルキル基で置換されていてもよいカルバモイル基を表し、
ここにおいて、置換されていてもよいアルキル基における置換基は、水酸基;オキソ基;シアノ基;アルコキシ基;アルカノイル基;カルボキシル基;アルコキシカルボニル基;カルボキシル基で置換されていてもよい脂肪族複素環カルボニル基;水酸基、又はオキソ基で置換されていてもよいヘテロアリール基;1~2個のオキソ基で置換されていてもよい脂肪族複素環基;アルキル基(該アルキル部分は水酸基、アルコキシ基、又はカルボキシル基で置換されていてもよい)、及び水酸基からなる群より独立して選ばれる1~2の基で置換されていてもよいカルバモイル基;アルキルスルホニル基;1~2個のアルキル基で置換されていてもよいアミノスルホニル基;1~2個のアルキル基で置換されていてもよいアミノスルホニルアミノカルボニル基;アルキルスルホニルアミノカルボニル基;及び、アルキル基、アルカノイル基、及びアルキルスルホニル基からなる群より独立して選ばれる1~2の基で置換されていてもよいアミノ基からなる群より独立して選ばれる1~2の基であり、
また、置換されていてもよいアルケニル基、置換されていてもよいシクロアルキル基、置換されていてもよいシクロアルケニル基、置換されていてもよいアリール基、置換されていてもよいヘテロアリール基、置換されていてもよい脂肪族複素環基、及び置換されていてもよいアルコキシ基における置換基は、水酸基;オキソ基;シアノ基;カルボキシル基で置換されていてもよいアルキル基;アルコキシ基;アルカノイル基;カルボキシル基;アルコキシカルボニル基;カルボキシル基で置換されていてもよい脂肪族複素環カルボニル基;水酸基、又はオキソ基で置換されていてもよいヘテロアリール基;1~2個のオキソ基で置換されていてもよい脂肪族複素環基;アルキル基(該アルキル部分は水酸基、アルコキシ基、又はカルボキシル基で置換されていてもよい)、及び水酸基からなる群より独立して選ばれる1~2の基で置換されていてもよいカルバモイル基;アルキルスルホニル基;1~2個のアルキル基で置換されていてもよいアミノスルホニル基;1~2個のアルキル基で置換されていてもよいアミノスルホニルアミノカルボニル基;アルキルスルホニルアミノカルボニル基;及び、アルキル基、アルカノイル基、及びアルキルスルホニル基からなる群より独立して選ばれる1~2の基で置換されていてもよいアミノ基からなる群より独立して選ばれる1~2の基であり;
R6及びR7は各々独立して、水素原子、ハロゲン原子、シアノ基、アルキル基、ハロアルキル基、及びハロアルコキシ基からなる群より選ばれる基を表す。
R1がアルコキシ基及びシアノ基からなる群より選ばれる基で置換されていてもよい5~6員単環式シクロアルキル基であり、
R2がハロゲン原子、又はアルコキシ基であり、
環Bがピロリジニル基であり、かつR3がアルコキシアルキル基であり、R4が水素原子、又はハロゲン原子であり、
環Cがフェニル基であり、
R5がカルボキシル基で置換されたピペリジニル基であり、
R6がハロゲン原子、又はハロアルキル基であり、
R7が水素原子である、化合物、もしくはその医薬的に許容し得る塩又は共結晶を包含する。
1-{2-[(3S,5S)-1-{[(3R,4R)-1-(trans-4-エトキシシクロヘキシル)-3-メトキシ-4-(4-メトキシフェニル)ピロリジン-3-イル]カルボニル}-5-(エトキシメチル)ピロリジン-3-イル]-5-(トリフルオロメチル)フェニル}ピペリジン-4-カルボン酸;
1-{2-[(3S,5S)-1-{[(3R,4R)-3-フルオロ-4-(4-メトキシフェニル)-1-(2-メチルピリジン-4-イル)ピロリジン-3-イル]カルボニル}-5-(メトキシメチル)ピロリジン-3-イル]-5-(トリフルオロメチル)フェニル}ピペリジン-4-カルボン酸;
1-{2-[(3S,5S)-1-{[(3R,4R)-3-フルオロ-4-(4-メトキシフェニル)-1-(2-メチルピリミジン-4-イル)ピロリジン-3-イル]カルボニル}-5-(メトキシメチル)ピロリジン-3-イル]-5-(トリフルオロメチル)フェニル}ピペリジン-4-カルボン酸;
1-{5-フルオロ-2-[(3S,5S)-1-{[(3R,4R)-3-フルオロ-1-(trans-4-メトキシシクロヘキシル)-4-(4-メトキシフェニル)ピロリジン-3-イル]カルボニル}-5-(メトキシメチル)ピロリジン-3-イル]フェニル}ピペリジン-4-カルボン酸;
1-{2-[(3S,5S)-1-{[(3R,4R)-1-(trans-4-エトキシシクロヘキシル)-3-メトキシ-4-(4-メトキシフェニル)ピロリジン-3-イル]カルボニル}-5-(メトキシメチル)ピロリジン-3-イル]-5-(トリフルオロメチル)フェニル}ピペリジン-4-カルボン酸;
1-{2-[(3S,5S)-1-{[(3R,4R)-1-(trans-4-シアノシクロヘキシル)-3-フルオロ-4-(4-メトキシフェニル)ピロリジン-3-イル]カルボニル}-5-(メトキシメチル)ピロリジン-3-イル]- 5-(トリフルオロメチル)フェニル}ピペリジン-4-カルボン酸;
1-{2-[(3S,4S)-1-{[(3R,4R)-1-(trans-4-エトキシシクロヘキシル)-3-メトキシ-4-(4-メトキシフェニル)ピロリジン-3-イル]カルボニル}-4-フルオロ-4-(メトキシメチル)ピロリジン-3-イル]-5-(トリフルオロメチル)フェニル}ピペリジン-4-カルボン酸;
1-{2-[(3S,4R)-1-{[(3R,4R)-1-(trans-4-エトキシシクロヘキシル)-3-メトキシ-4-(4-メトキシフェニル)ピロリジン-3-イル]カルボニル}-4-(メトキシメチル)ピロリジン-3-イル]-5-(トリフルオロメチル)フェニル}ピペリジン-4-カルボン酸;
1-{2-[(3S,5S)-1-{[(3R,4R)-1-シクロヘキシル-3-フルオロ-4-(4-メトキシフェニル)ピロリジン-3-イル]カルボニル}-5-(メトキシメチル)ピロリジン-3-イル]-5-(トリフルオロメチル)フェニル}ピペリジン-4-カルボン酸;
1-{2-[(3S,5S)-1-{[(3R,4R)-3-フルオロ-4-(4-メトキシフェニル)-1-(テトラヒドロ-2H-ピラン-4-イル)ピロリジン-3-イル]カルボニル}-5-(メトキシメチル)ピロリジン-3-イル] -5-(トリフルオロメチル)フェニル}ピペリジン-4-カルボン酸;
1-{2-[(3S,5S)-1-{[(3R,4R)-3-フルオロ-1-(trans-4-メトキシシクロヘキシル)-4-(4-メトキシフェニル)ピロリジン-3-イル]カルボニル}-5-(メトキシメチル)ピロリジン-3-イル]-5-(トリフルオロメチル)フェニル}ピペリジン-4-カルボン酸;
1-{2-[(3S,5S)-1-{[(3R,4R)-1-シクロペンチル-3-フルオロ-4-(4-メトキシフェニル)ピロリジン-3-イル]カルボニル}-5-(メトキシメチル)ピロリジン-3-イル]-5-(トリフルオロメチル)フェニル}ピペリジン-4-カルボン酸;
1-{2-[(3S,4R)-1-{[(3R,4R)-3-フルオロ-4-(4-メトキシフェニル)-1-(2-メチルピリジン-4-イル)ピロリジン-3-イル]カルボニル}-4-(メトキシメチル)ピロリジン-3-イル]-5-(トリフルオロメチル)フェニル}ピペリジン-4-カルボン酸;
1-{2-[(3S,4S)-4-フルオロ-1-{[(3R,4R)-3-フルオロ-1-(trans-4-メトキシシクロヘキシル)-4-(4-メトキシフェニル)ピロリジン-3-イル]カルボニル}-4-(メトキシメチル)ピロリジン-3-イル]-5-(トリフルオロメチル)フェニル}ピペリジン-4-カルボン酸;
1-{5-クロロ-2-[(3S,4R)-1-{[(3R,4R)-3-フルオロ-1-(trans-4-メトキシシクロヘキシル) -4-(4-メトキシフェニル)ピロリジン-3-イル]カルボニル}-4-(メトキシメチル)ピロリジン-3-イル]フェニル}ピペリジン-4-カルボン酸;
1-{2-[(3S,4R)-4-(シアノメチル)-1-{[(3R,4R)-1-シクロペンチル-3-フルオロ-4-(4-メトキシフェニル)ピロリジン-3-イル]カルボニル}ピロリジン-3-イル]-5-(トリフルオロメチル)フェニル}ピペリジン-4-カルボン酸;
1-{2-[(3S,4R)-1-{[(3R,4R)-3-フルオロ-1-(trans-4-メトキシシクロヘキシル)-4-(4-メトキシフェニル)ピロリジン-3-イル]カルボニル}-4-(メトキシメチル)ピロリジン-3-イル]-5-(トリフルオロメチル)フェニル}ピペリジン-4-カルボン酸;
1-[2-(1-{[(3R,4R)-3-フルオロ-1-(trans-4-メトキシシクロヘキシル)-4-(4-メトキシフェニル)ピロリジン-3-イル]カルボニル}ピペリジン-4-イル)-5-(トリフルオロメチル)フェニル]ピペリジン-4-カルボン酸;
1-{2-[(3S,4R)-1-{[(3R,4R)-1-シクロペンチル-3-フルオロ-4-(4-メトキシフェニル)ピロリジン-3-イル]カルボニル}-4-(メトキシメチル)ピロリジン-3-イル]-5-(トリフルオロメチル)フェニル}ピペリジン-4-カルボン酸;及び
1-{2-[(3S)-1-{[(3R,4R)-3-フルオロ-1-(trans-4-メトキシシクロヘキシル)-4-(4-メトキシフェニル)ピロリジン-3-イル]カルボニル}ピロリジン-3-イル]-5-(トリフルオロメチル)フェニル}ピペリジン-4-カルボン酸
からなる群より選ばれる化合物もしくはその医薬的に許容しうる塩又は共結晶が挙げられる。
また、一般式[I]の化合物は、幾何異性体としてcis-及びtrans-異性体を含み得て、更に分子内に軸不斉を有する場合には軸不斉に基づく異性体を含み得て、これらの内のいずれか1個の異性体又はその混合物をいずれも包含するものである。
一般式[I]の化合物もしくはその医薬的に許容しうる塩又は共結晶は、優れたMC1Rアゴニスト活性を有し、それにより、インビボにおいても主にメラニン産生細胞におけるメラニン産生を促進し、皮膚の色素沈着を促進する。したがって、一般式[I]の化合物もしくはその医薬的に許容しうる塩又は共結晶を有効成分として含有する医薬は、MC1Rの活性化を通じて主にメラニン産生を促進することにより改善が見込まれる状態、例えば、光線性皮膚疾患(光線過敏症とも呼ばれる)や低色素性疾患や光線療法の副作用などを治療又は予防するために有用である。
光線性皮膚疾患としては、光アレルギー性皮膚炎、種痘様水疱症、DNA修復異常症、およびポルフィリン症(プロトポルフィリン症を除く)が挙げられる。
光アレルギー性皮膚炎としては、日光蕁麻疹、多形日光疹、慢性光線性皮膚炎、光アレルギー性接触皮膚炎、光アレルギー性光線過敏症型薬疹などが挙げられる。
DNA修復異常症としては、色素性乾皮症、ブルーム症候群、ウェルナー症候群、ロスムンド・トムスン症候群、硫黄欠乏性毛髪発育異常症、紫外線高感受性症候群などが挙げられる。
ポルフィリン症(プロトポルフィリン症を除く)としては、先天性骨髄性ポルフィリン症、異型ポルフィリン症、急性間欠性ポルフィリン症、晩発性皮膚ポルフィリン症、遺伝性コプロポルフィリン症などが挙げられる。
低色素性疾患としては、眼皮膚白皮症、まだら症、脱色素性母斑、低色素症(伊藤白斑)、フェニルケトン尿症、結節性硬化症、遺伝性対側性色素異常症、ワールデンブルグ症候群、ヘルマンスキー・プドラック症候群、チェディアックー東症候群、グリセリ症候群、ティーツ症候群などの先天性低色素性疾患、およびサットン白斑、フォークト-小柳-原田病、老人性白斑、海水浴後白斑、梅毒性白斑などの後天性低色素性疾患が挙げられる。
“Photodermatoses in Pigmented Skin”, Vinod Kumar Sharma et al., Photochem Photobiol Sci, 12 (1), 65-77 Jan 2013
光線過敏性のDNA修復異常疾患である色素性乾皮症は、例えばin vitro試験ではMoriwakiらが診療ガイドラインで報告している紫外線照射後の不定期DNA合成試験や紫外線致死感受性試験(コロニー形成法)などが(J Dermatol 2017, 44, 1087)、in vivo試験ではKunisadaらが報告しているXpaノックアウトマウスに紫外線を照射して皮膚の炎症や皮膚がんを誘発する試験系があり(J Invest Dermatol 2017, 137, 1975)、治療効果を評価する方法として知られており、他にNakazawaらが報告しているPolr2aKR/KR/Xpa-/-遺伝子改変マウスモデルも用いることができる(Cell 2020, 180, 1228)。
医薬的に許容し得る塩、共結晶、分子内塩、付加物等としては、例えば、塩酸、硫酸、リン酸又は臭化水素酸の如き無機酸、酢酸、フマル酸、シュウ酸、クエン酸、メタンスルホン酸、ベンゼンスルホン酸、トシル酸又はマレイン酸の如き有機酸等を含むものが挙げられる。
一般式[I]の化合物の共結晶として、一般式[I]の化合物とリン酸との共結晶が好ましく使用できる。特に、化合物Aとリン酸との共結晶は、特許文献8記載の方法に従って得ることができる。
一般式[I]の化合物もしくはその医薬的に許容しうる塩又は共結晶を含む医薬の投与量は、低毒性で安全に使用することができ、光線性皮膚疾患、低色素性疾患、光線療法の副作用、白髪などの疾患や状態に対して治療効果又は予防効果を発揮できる量であれば特に制限はされないが、例えば、一般式[I]の化合物の量として、1~1000mg/日、好ましくは10~500mg/日である。より確実に皮膚の色素沈着を促進し、光線性皮膚疾患、低色素性疾患、光線療法の副作用、白髪などの疾患や状態に対して治療効果又は予防効果を発揮するためには、一般式[I]の化合物の量として、50~500mg/日が好ましく、80~400mg/日がより好ましく、100~300mg/日が特に好ましく、例えば、100mg/日、150mg/日、200mg/日、250mg/日、300mg/日もしくはこれらの間の投与量が例示される。
特に経口投与が好ましく、一般式[I]の化合物もしくはその医薬的に許容しうる塩又は共結晶を含む医薬は、経口的に、一般式[I]の化合物の量として、例えば、50~500mg/日、好ましくは80~400mg/日、より好ましくは100~300mg/日、具体的には、100mg/日、150mg/日、200mg/日、250mg/日、300mg/日もしくはこれらの間の投与量で投与される。
化合物A
1-{2-[(3S,4R)-1-{[(3R,4R)-1-シクロペンチル-3-フルオロ-4-(4-メトキシフェニル)ピロリジン-3-イル]カルボニル}-4-(メトキシメチル)ピロリジン-3-イル]-5-(トリフルオロメチル)フェニル}ピペリジン-4-カルボン酸とリン酸の共結晶
化合物B
1-{2-[(3S,5S)-1-{[(3R,4R)-1-(trans-4-エトキシシクロヘキシル)-3-メトキシ-4-(4-メトキシフェニル)ピロリジン-3-イル]カルボニル}-5-(メトキシメチル)ピロリジン-3-イル]-5-(トリフルオロメチル)フェニル}ピペリジン-4-カルボン酸・2塩酸塩
すなわち、1-{2-[(3S,4R)-1-{[(3R,4R)-1-シクロペンチル-3-フルオロ-4-(4-メトキシフェニル)ピロリジン-3-イル]カルボニル}-4-(メトキシメチル)ピロリジン-3-イル]-5-(トリフルオロメチル)フェニル}ピペリジン-4-カルボン酸 1/2エタン-1,2-ジスルホン酸(19.3kg)の酢酸エチル(86.6kg)懸濁液に、20~30℃で炭酸カリウム(3.4kg)の水(77.0L)溶液及び水(19.3L)を順に加え、混合物を10分間撹拌した。静置後に水層を除き、有機層を水(96.3L)で2回洗浄した。有機層を35Lまで濃縮した後、エタノール(75.9kg)を加え、35Lまで濃縮した。エタノール(30.3kg)で希釈後、不溶物をろ過し、エタノール(75.6kg)で洗浄した。ろ洗液を35Lまで濃縮し、エタノール(17.9kg)で希釈した。20~30℃で24%水酸化ナトリウム水溶液(6.1kg)及び水(15.6kg)を順に加え、混合物を20~30℃で5時間撹拌した。20~40℃でリン酸(8.5kg)の水(28.9L)溶液及び水(115.5L)を順に加えた。30~40℃で化合物A(0.48kg)を種晶として加え、19.5時間撹拌した後に20℃に冷却した。固体を濾取し、該固体を水(96.3L)で洗浄した。固体を50℃以下で乾燥した後、粉砕し、化合物A(17.5kg)を得た。
取得した化合物AはIRを用いて同定した。
1-{2-[(3S,5S)-1-{[(3R,4R)-1-(trans-4-エトキシシクロヘキシル)-3-メトキシ-4-(4-メトキシフェニル)ピロリジン-3-イル]カルボニル}-5-(メトキシメチル)ピロリジン-3-イル]-5-(トリフルオロメチル)フェニル}ピペリジン-4-カルボン酸(化合物Bのフリー体)も特許文献7に記載の方法で製造し、その塩酸塩は常法に従って製造した。
[ヒト及びマウスMC1R アゴニスト活性測定(cAMP測定)]
ヒトMC1R又はマウスMC1Rを安定発現させたヒト胎児腎細胞293(HEK293)細胞を用いた。各濃度の化合物溶液をcAMPアッセイバッファー(10mM HEPES、1%BSAを含むHBSS(Hank's Balanced Salt Solution))と混和し、96 well black half areaプレートに分注した。ヒトMC1R発現細胞(3×103 cells/well)又はマウスMC1R発現細胞(18×103 cells/well)は、0.5 mM IBMXを含むcAMPアッセイバッファーに懸濁し、上記96 wellプレートに分注後に混和し、37℃ 30分間静置後、細胞内cAMP濃度を Envisionを用いた蛍光法により測定した(ex. 320 nm,em. 665 nm及び615 nm)。得られたデータは、ratio値(665 nm測定値 / 615 nm測定値 × 10000)から、Prism 5.02を用いてcAMP濃度の定量値を算出し、αMSH、化合物A及びNDP-αMSH([Nle4,D-Phe7]-α-MSH)の最大反応量Emax及びEC50(αMSHのEmax の1/2の反応を示す濃度 )を非線形回帰により算出した。
[ヒトMCRサブタイプに対する結合選択性評価]
化合物AのMC1R、MC3R、MC4R及びMC5Rに対する結合性は、放射性標識リガンド([125I]NDP-α-MSH)結合アッセイにより評価した。
MC1R、MC3R、MC4R及びMC5Rに対する作用評価には、以下に記載した実験条件で実施した。
I. バッファー:
1. インキュベーションバッファー: 25 mmol/L HEPES, pH 7.0、100 mmol/L NaCl、1 mmol/L 1,10-Phenanthroline、1.5 mmol/L CaCl2、1 mmol/L MgSO4、one CompleteTMprotease inhibitor tablet/100 mL
2. 洗浄バッファー: 50 mmol/L Tris-HCl, pH 7.4
ヒトリコンビナントMC1R(PerkinElmer)をインキュベーションバッファーに溶解した。
反応液
被験物質溶液又はvehicle (1% DMSO*): 2.2 μL
0.04 nmol/L* [125I]NDP-α-MSH in 20% BSA: 20 μL
8.33 μg/mL 受容体溶液:200 μL
* 評価時の終濃度
2. GF/Bフィルターマットを用いて吸引濾過することにより受容体/[125I]NDP-α-MSHの複合体を回収した。その後、洗浄バッファーで洗浄した。
3. 放射能量をシンチレーションカウンター(Top Count NXT, PerkinElmer)で測定した。
I. バッファー:
1. インキュベーションバッファー: 25 mmol/L HEPES, pH 7.0、100 mmol/L NaCl、1 mmol/L 1,10-Phenanthroline、1.5 mmol/L CaCl2、1 mmol/L MgSO4、one CompleteTMprotease inhibitor tablet/100 mL
2. 洗浄バッファー: 50 mmol/L Tris-HCl, pH 7.4
ヒトリコンビナントMC3R(PerkinElmer)をインキュベーションバッファーに溶解した。
反応液
被験物質溶液又はvehicle (1% DMSO*): 2.2 μL
0.035 nmol/L* [125I]NDP-α-MSH in 20% BSA: 20 μL
24 μg/mL 受容体溶液: 200 μL
* 評価時の終濃度
2. GF/Bフィルターマットを用いて吸引濾過することにより受容体/[125I]NDP-α-MSHの複合体を回収した。その後、洗浄バッファーで洗浄した。
3. 放射能量をシンチレーションカウンター(Top Count NXT, PerkinElmer)で測定した。
I. バッファー:
1. インキュベーションバッファー: 25 mmol/L HEPES, pH 7.0、1.5 mmol/L CaCl2、1 mmol/L MgSO4、100 mmol/L NaCl、1 mmol/L 1,10-Phenanthroline、one CompleteTMprotease inhibitor tablet/100 mL
2. 洗浄バッファー: 50 mmol/L Tris-HCl, pH 7.4
ヒトリコンビナントMC4R(PerkinElmer)をインキュベーションバッファーに溶解した。
反応液
被験物質溶液又はvehicle (1% DMSO*): 2.2 μL
0.02 nmol/L* [125I]NDP-α-MSH in 20% BSA: 20 μL
6.67 μg/mL 受容体溶液:200 μL
* 評価時の終濃度
2. GF/Bフィルターマットを用いて吸引濾過することにより受容体/[125I]NDP-α-MSHの複合体を回収した。その後、洗浄バッファーで洗浄した。
3. 放射能量をシンチレーションカウンター(Top Count NXT, PerkinElmer)で測定した。
I. バッファー:
1. インキュベーションバッファー: 25 mmol/L HEPES, pH 7.0、100 mmol/L NaCl、 1 mmol/L 1,10-Phenanthroline、1.5 mmol/L CaCl2, 1 mmol/L MgSO4, one completeTM protease inhibitior tablet/100 mL
2. 洗浄バッファー: 50 mmol/L Tris-HCl, pH 7.4
ヒトリコンビナントMC5R(PerkinElmer)をインキュベーションバッファーに溶解した。
反応液
被験物質溶液又はvehicle (1% DMSO*): 2.2 μL
0.035 nmol/L* [125I]NDP-α-MSH in 20% BSA: 20 μL
24 μg/mL 受容体溶液: 200 μL
* 評価時の終濃度
2. GF/Bフィルターマットを用いて吸引濾過することにより受容体/[125I]NDP-α-MSHの複合体を回収した。その後、洗浄バッファーで洗浄した。
3. 放射能量をシンチレーションカウンター(Top Count NXT, PerkinElmer)で測定した。
1. 阻害率の算出
被験物質の各濃度における阻害率は、下記の計算式により算出した。
阻害率(%) = {1 - (c-a) / (b-a)} x 100
a: 非特異的放射能量(平均cpm値)
b: 被験物質非存在下での放射線量(平均cpm値)
c: 被験物質存在下での放射線量(個別cpm値)
被験物質のIC50値は、下記の回帰式により算出した。
Y= Bottom + (Top - Bottom) / {1 + 10(Log IC50 - X) x nH}
Xは、濃度の常用対数値とした。
Yは、Bottom(0)とTop(100)をもつシグモイド曲線に当てはめた。
nH: variable Hill slope。
被験物質のKi値は、下記の計算式により算出した。
Ki = IC50 / (1 + [Ligand] / Kd)
[Ligand]: アッセイに用いた放射性リガンド濃度
Kd: 放射性リガンドの各受容体への結合の解離定数は、試験実施施設であるEurophins Panlabsのヒストリカルデータを参照した。
MathIQTM(version 2.0.1.8; ID Business Solutions Ltd., UK)
Prism (version 4.03; GraphPad Software, Inc)
[マウスメラノーマ細胞株に対するメラニン産生活性測定]
以下の手順でMC1R作動薬のマウスメラノーマ細胞株からのメラニン産生に対する作用を評価した。
メラニン産生活性測定には、マウス黒色腫由来細胞株B16F1細胞を用いた。B16F1細胞の培養には、10% fetal bovine serum(FBS)及び100U/mL Penicillin-Streptomycinを含むDulbecco's Modified Eagle Medium(DMEM)を使用した。
96 wellプレートにB16F1細胞(1.5×104cells/well)を播種し、各濃度の化合物溶液を含有する培養培地を上記の96 wellプレートに添加した後、インキュベーター(37℃、5% CO2設定)にて3日間培養した。メラニン溶液を標準液として用い、マイクロプレートリーダーVERSAmaxを用いて、培養上清の吸光度(405nm)測定することにより、培地中のメラニン濃度を定量した。NDP-αMSH、及び化合物Aの各濃度群のメラニン産生量の中央値を算出し、下記の計算式より、各中央値のメラニン産生量のΔ値を算出した。1回の実験はtripricateで実施し、3回の独立した実験を行った。
Δ値 = A-B
A:各試験物質の各濃度群のメラニン産生量の中央値
B:DMSO群のメラニン産生量の中央値
NDP-αMSHの各濃度群Δ値を用い、非線形回帰によりNDP-αMSH の最大Δ値を算出した。この最大Δ値を100%とし、NDP-αMSH及び化合物Aの各濃度群Δ値を下記の計算式により百分率換算し、%値を算出した。
%値= C/D x 100
C:各試験物質の各濃度群のΔ値
D:非線形回帰により算出したNDP-αMSHの最大Δ値
また、化合物A及びNDP-αMSH([Nle4,D-Phe7]-α-MSH)のEC50(NDP-αMSHのEmax の1/2の反応を示す濃度 )を非線形回帰により算出した。
ネガティブコントロールとの%値の差は、実験回の対応を考慮し、群及び実験回を要因にした二元配置のDunnett検定を実施した。このとき、有意水準としては両側5%とした。以上の解析に関しては、SASを用いて実施した。
[マウス体毛黒色化作用の検討]
以下の手順でMC1R作動薬のC57BL/6J-Ay/aマウスに対する体毛黒色化作用を評価した。
雄性C57BL/6JHamSlc-Ay/+マウス(日本SLC株式会社株式会社)を使用した。毛周期が成長期にある個体を用いるために、29又は30日齢に日齢を合わせて試験を実施した。投与開始前にマウス背部をバリカンで剃毛し、切り傷やあざ等の皮膚に異常のない個体を選抜し、表3に示す群構成で各群の体重が均質になるようにシミュレーション法を行いて群わけした。被験物質の投与(調製も含む)と体毛の評価をそれぞれ別の実験者が分担し、盲検化して評価を実施した。投与開始日をday 0として、6日間(day 0 - day 5)被験物質を1日1回投与した。
化合物A:フリー体換算として必要量を秤量し、目的濃度となるように0.5%(w/v) メチルセルロース(0.5%MC) 水溶液に懸濁させた。0.1 mL/10 g (体重)の容量で経口投与した。
NDP-αMSH(対照薬): フリー体換算として必要量を秤量し、Dulbecco’s phosphate-buffered saline(PBS)にて0.4 mg/mLの濃度に溶解した。0.05 mL/10 g (体重)の容量で皮下投与した。
評価と採材をday 6に実施した。マウスを頸椎脱臼により安楽死させた後に、背部をバリカンで剃毛し、体毛の黒色度から、個体ごとに黒色化陽性(+)又は陰性(-)を判定した。
統計解析方法はSASを用いて実施し、有意水準は0.05とした。評価項目に関して0.5%MC投与群とNDP-αMSH群をFisherの直接確率法で解析した。0.5%MC投与群と化合物Aの各投与群との比較をFisherの直接確率法(固定順検定)で解析した。固定順検定としては、高用量からFisherの直接確率法を行い、有意であれば、同様に下の用量の解析を行った。
健常人を対象とした化合物Aの臨床試験における皮膚のメラニン関連遺伝子発現
年齢18歳から55歳までの健康な白人男性を対象にランダム化二重盲検臨床試験にて、化合物Aが単回経口投与された。対象者はプラセボ8例、化合物Aの30、100、300、600mg各用量に6例に割り付けられた。対象者は薬剤投与の前日及び投与一日後に背部皮膚組織小片を生検パンチで採取された。ヒト皮膚組織mRNA発現強度はアフィメトリクス社のジーンチップヒト遺伝子2.0STアレイシステム(カタログ番号902112)を用いてキットのインストラクションを参考にして測定された。メラニン合成関連遺伝子であるチロシナーゼ関連蛋白1(TYRP1)及びプレメラノソーム蛋白(PMEL)に関して、薬剤投与の前日の遺伝子発現量を基準にして投与翌日の遺伝子発現の変化率及びその有意差検定した。
健常人を対象とした化合物Aの臨床試験における皮膚メラニン密度推移
年齢18歳から55歳までの健康男性を対象にランダム化二重盲検試験にて、化合物Aが1日1回14日間反復経口投与された。対象者はプラセボ12例、化合物Aの30、150、300、450mg各用量に9例に割り付けられた。投薬前の時点での対象者の肌の色はフィッツパトリック皮膚分類にて判定され、プラセボ群ではタイプIIIからV、化合物Aの30から300mg投与群ではタイプIIからIV、450mg投与群ではタイプVだった。皮膚メラニン密度の測定はコニカミノルタ製分光測色計(型番CM-600d)を用いて製品マニュアルを参考にして測定された。
紫外線A照射マウス光老化モデル
<試験動物及び試験デザイン>
雄性アルビノ性ヘアレスマウス(系統名Hos:HR-1、株式会社星野試験動物飼育所)を使用した。各群のマウス体重が均質になるように群分けを行い、その翌日より無処置群以外の群には週5回の頻度で8週間漸増的に紫外線Aをマウス背部皮膚に照射して、皮膚の光老化を惹起させた。なお,紫外線A照射スケジュールはMinamiらの報告(J Nutrition Biochem 2009, 20, 389)を参考にした。
化合物B:フリー体換算として必要量を秤量し、目的濃度になるように0.5%MCに懸濁させた。0.1mL/10g(体重)の容量で1日1回8週間3mg/kgにて経口投与した。
HP-228(対照薬,メラノコルチン作動ペプチド):フリー体換算として必要量を秤量し、目的濃度になるようにPBSに溶解させた。0.1mL/10g(体重)の容量で1日1回8週間3mg/kgにて腹腔内注射した。
肉眼的観察による皮膚のしわの評価(評価項目a):紫外線A照射した8週間に週1回の頻度で皮膚のしわの状態をスコア0(微細なしわ)から3(深くて粗いしわ)までの4段階で評価した。
皮膚中I型コラーゲン含量の定量(評価項目b):紫外線A照射8週後にマウスを安楽死させて背部皮膚を摘出した。採材皮膚に酢酸とペプシンを添加してホモジネートを作製した。紫外線Aで減少した皮膚ホモジネート中のコラーゲン量をMouse Collagen Type I ELISA Kitを用いて測定した。
皮膚組織学的検査(評価項目c):採材皮膚を10%中性緩衝ホルマリンで固定した後パラフィン切片を作成した。抗シクロブタン型ピリミジンダイマー(CPD)抗体(コスモバイオ社)を用いた酵素抗体法免疫染色法にて、紫外線Aで誘発されたDNA損傷を検出した。
皮膚しわスコアは多重性を調整したMann-WhitneyのU検定を行い、有意水準は0.05とした。コラーゲン量の有意差検定はt検定あるいはDunnett多重比較検定で行い、有意水準は0.05とした。
評価項目aの結果を図3に示す。化合物B投与群及びHP-228投与群の皮膚しわスコアはどちらも溶媒対照群と比較して低値または低値傾向で推移し、一定の抗光老化作用を有する可能性が示された。
評価項目bの結果を図4に示す。溶媒対照群の皮膚中のI型コラーゲン量は紫外線A照射によって分解されて無処置群と比較して有意に低下した。化合物B投与群及びHP-228投与群の皮膚中I型コラーゲン量はどちらも溶媒対照群と比較して有意に高値を示し、紫外線Aで惹起された皮膚コラーゲン分解を化合物Bが抑制したことが示された。
評価項目cの結果を表6に示す。CPDは紫外線によって誘発されるDNA損傷マーカーであり、紫外線A照射によって皮膚における陽性の程度が増加した。そして、化合物B投与群及びHP-228投与群の表皮CPD染色はどちらも溶媒対照群と比べて陽性の程度が弱い傾向であった。以上のことから、化合物Bはメラニン産生作用以外の効果も発揮して光線性皮膚疾患を治療あるいは予防できる可能性が示された。
Claims (11)
- 一般式[I]で表される化合物もしくはその医薬的に許容しうる塩又は共結晶を有効成分とする、メラニン産生を促進することにより治療又は予防しうる状態(プロトポルフィリン症および白斑症(尋常性白斑)を除く)を治療又は予防するための医薬。
ここにおいて、置換されていてもよいアリール基、及び置換されていてもよいヘテロアリール基における置換基は、ハロゲン原子、アルキル基、ハロアルキル基、シクロアルキル基、アルコキシ基、ハロアルコキシ基、及びアルキレンオキシ基からなる群より独立して選ばれる1~3の基であり;
R1は置換されていてもよいアルキル基、置換されていてもよいシクロアルキル基、置換されていてもよい脂肪族複素環基、置換されていてもよく部分的に水素化されていてもよいアリール基、置換されていてもよいヘテロアリール基、又は1~2個のアルキル基で置換されていてもよいカルバモイル基を表し、
ここにおいて、置換されていてもよいアルキル基における置換基は、ハロゲン原子;水酸基;オキソ基;シアノ基;シクロアルキル基;アルコキシ基;アルカノイル基;1~2個のアルキル基で置換されていてもよいカルバモイル基;脂肪族複素環基;ハロゲン原子、アルキル基、ハロアルキル基、及びアルコキシアルキル基からなる群より独立して選ばれる1~2の基で置換されていてもよい脂肪族複素環カルボニル基;アルキルスルホニル基;脂肪族複素環スルホニル基;及びアルキレンオキシ基からなる群より独立して選ばれる1~3の基であり、
また、置換されていてもよいシクロアルキル基、置換されていてもよい脂肪族複素環基、置換されていてもよく部分的に水素化されていてもよいアリール基、及び置換されていてもよいヘテロアリール基における置換基は、ハロゲン原子;水酸基;オキソ基;シアノ基;アルキル基;ハロアルキル基;シクロアルキル基;アルコキシ基;ヒドロキシアルキル基;アルコキシアルキル基;アルカノイル基;1~2個のアルキル基で置換されていてもよいカルバモイル基;脂肪族複素環基;ハロゲン原子、アルキル基、ハロアルキル基、及びアルコキシアルキル基からなる群より独立して選ばれる1~2の基で置換されていてもよい脂肪族複素環カルボニル基;アルキルスルホニル基;脂肪族複素環スルホニル基;及びアルキレンオキシ基からなる群より独立して選ばれる1~3の基であり;
R2はハロゲン原子、アルキル基、又はアルコキシ基を表し;
環Bは、部分的に二重結合を含んでいてもよい含窒素脂肪族複素環基を表し、
環Cはアリール基、又はヘテロアリール基を表し、
R3及びR4は各々独立して、水素原子、ハロゲン原子、シアノ基、アルキル基、ハロアルキル基、シアノアルキル基、ヒドロキシアルキル基、アルコキシアルキル基、カルボキシル基、1~2個のアルキル基で置換されていてもよいカルバモイル基、及びアルコキシ基からなる群より選ばれる基を表し;
R5は置換されていてもよいアルキル基、置換されていてもよいアルケニル基、置換されていてもよいシクロアルキル基、置換されていてもよいシクロアルケニル基、置換されていてもよいアリール基、置換されていてもよいヘテロアリール基、置換されていてもよい脂肪族複素環基、置換されていてもよいアルコキシ基、カルボキシル基で置換されていてもよい1~2個のアルキル基で置換されていてもよいアミノ基、又はカルボキシル基で置換されていてもよい1~2個のアルキル基で置換されていてもよいカルバモイル基を表し、
ここにおいて、置換されていてもよいアルキル基における置換基は、水酸基;オキソ基;シアノ基;アルコキシ基;アルカノイル基;カルボキシル基;アルコキシカルボニル基;カルボキシル基で置換されていてもよい脂肪族複素環カルボニル基;水酸基、又はオキソ基で置換されていてもよいヘテロアリール基;1~2個のオキソ基で置換されていてもよい脂肪族複素環基;アルキル基(該アルキル部分は水酸基、アルコキシ基、又はカルボキシル基で置換されていてもよい)、及び水酸基からなる群より独立して選ばれる1~2の基で置換されていてもよいカルバモイル基;アルキルスルホニル基;1~2個のアルキル基で置換されていてもよいアミノスルホニル基;1~2個のアルキル基で置換されていてもよいアミノスルホニルアミノカルボニル基;アルキルスルホニルアミノカルボニル基;及び、アルキル基、アルカノイル基、及びアルキルスルホニル基からなる群より独立して選ばれる1~2の基で置換されていてもよいアミノ基からなる群より独立して選ばれる1~2の基であり、
また、置換されていてもよいアルケニル基、置換されていてもよいシクロアルキル基、置換されていてもよいシクロアルケニル基、置換されていてもよいアリール基、置換されていてもよいヘテロアリール基、置換されていてもよい脂肪族複素環基、及び置換されていてもよいアルコキシ基における置換基は、水酸基;オキソ基;シアノ基;カルボキシル基で置換されていてもよいアルキル基;アルコキシ基;アルカノイル基;カルボキシル基;アルコキシカルボニル基;カルボキシル基で置換されていてもよい脂肪族複素環カルボニル基;水酸基、又はオキソ基で置換されていてもよいヘテロアリール基;1~2個のオキソ基で置換されていてもよい脂肪族複素環基;アルキル基(該アルキル部分は水酸基、アルコキシ基、又はカルボキシル基で置換されていてもよい)、及び水酸基からなる群より独立して選ばれる1~2の基で置換されていてもよいカルバモイル基;アルキルスルホニル基;1~2個のアルキル基で置換されていてもよいアミノスルホニル基;1~2個のアルキル基で置換されていてもよいアミノスルホニルアミノカルボニル基;アルキルスルホニルアミノカルボニル基;及び、アルキル基、アルカノイル基、及びアルキルスルホニル基からなる群より独立して選ばれる1~2の基で置換されていてもよいアミノ基からなる群より独立して選ばれる1~2の基であり;
R6及びR7は各々独立して、水素原子、ハロゲン原子、シアノ基、アルキル基、ハロアルキル基、及びハロアルコキシ基からなる群より選ばれる基を表す。 - 前記一般式[I]において、
環Aがアルコキシ基で置換されていてもよいフェニル基であり、
R1がアルコキシ基及びシアノ基からなる群より選ばれる基で置換されていてもよい5~6員単環式シクロアルキル基であり、
R2がハロゲン原子、又はアルコキシ基であり、
環Bがピロリジニル基であり、かつR3がアルコキシアルキル基であり、R4が水素原子、又はハロゲン原子であり、
環Cがフェニル基であり、
R5がカルボキシル基で置換されたピペリジニル基であり、
R6がハロゲン原子、又はハロアルキル基であり、
R7が水素原子である、
請求項1に記載の医薬。 - 前記一般式[I]で表される化合物が、1-{2-[(3S,4R)-1-{[(3R,4R)-1-シクロペンチル-3-フルオロ-4-(4-メトキシフェニル)ピロリジン-3-イル]カルボニル}-4-(メトキシメチル)ピロリジン-3-イル]-5-(トリフルオロメチル)フェニル}ピペリジン-4-カルボン酸である、請求項1に記載の医薬。
- 前記状態が光線性皮膚疾患(プロトポルフィリン症を除く)である、請求項1~3のいずれか一項に記載の医薬。
- 光線性皮膚疾患が光アレルギー性皮膚炎、種痘様水疱症、DNA修復異常症、またはポルフィリン症(プロトポルフィリン症を除く)である、請求項4に記載の医薬。
- 光アレルギー性皮膚炎が日光蕁麻疹、多形日光疹、慢性光線性皮膚炎、光アレルギー性接触皮膚炎、光アレルギー性光線過敏症型薬疹であり、
DNA修復異常症が色素性乾皮症、コケーン症候群、ブルーム症候群、ウェルナー症候群、ロスムンド・トムソン症候群、硫黄欠乏性毛髪発育異常症または紫外線高感受性症候群である、請求項5に記載の医薬。 - ポルフィリン症が、先天性骨髄性ポルフィリン症、異型ポルフィリン症、急性間欠性ポルフィリン症、晩発性皮膚ポルフィリン症、または遺伝性コプロポルフィリン症である、請求項5に記載の医薬。
- 前記状態が低色素性疾患(白斑症(尋常性白斑)を除く)である、請求項1~3のいずれか一項に記載の医薬。
- 低色素性疾患が、眼皮膚白皮症、まだら症、脱色素性母斑、低色素症(伊藤白斑)、フェニルケトン尿症、結節性硬化症、遺伝性対側性色素異常症、ワールデンブルグ症候群、ヘルマンスキー・プドラック症候群、チェディアックー東症候群、グリセリ症候群、ティーツ症候群を含む先天性低色素性疾患、およびサットン白斑、フォークト-小柳-原田病、老人性白斑、海水浴後白斑、梅毒性白斑を含む後天性低色素性疾患から選択される、請求項8に記載の医薬。
- 前記状態が光線療法の副作用である、請求項1~3のいずれか一項に記載の医薬。
- 前記状態が白髪である、請求項1~3のいずれか一項に記載の医薬。
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21821111.8A EP4166139A4 (en) | 2020-06-10 | 2021-06-10 | AGENTS FOR THE PREVENTION OR TREATMENT OF ACTINIC SKIN DISEASES |
IL298951A IL298951A (en) | 2020-06-10 | 2021-06-10 | Preventive or therapeutic agent for actinic skin disease |
CA3186882A CA3186882A1 (en) | 2020-06-10 | 2021-06-10 | Prophylactic or therapeutic agent for photodermatosis |
MX2022015806A MX2022015806A (es) | 2020-06-10 | 2021-06-10 | Agente profilactico o terapeutico para la fotodermatosis. |
JP2022530614A JPWO2021251452A1 (ja) | 2020-06-10 | 2021-06-10 | |
KR1020227045697A KR20230016008A (ko) | 2020-06-10 | 2021-06-10 | 광선성 피부질환의 예방 또는 치료제 |
CN202180041850.4A CN115768428A (zh) | 2020-06-10 | 2021-06-10 | 光照性皮肤病的预防或治疗剂 |
BR112022025115A BR112022025115A2 (pt) | 2020-06-10 | 2021-06-10 | Agente profilático ou terapêutico para fotodermatose |
US18/009,128 US20230226034A1 (en) | 2020-06-10 | 2021-06-10 | Prophylactic or therapeutic agent for photodermatosis |
AU2021289054A AU2021289054B2 (en) | 2020-06-10 | 2021-06-10 | Prophylactic or therapeutic agent for photodermatosis |
AU2024203990A AU2024203990A1 (en) | 2020-06-10 | 2024-06-12 | Prophylactic or therapeutic agent for photodermatosis |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020-101162 | 2020-06-10 | ||
JP2020101162 | 2020-06-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021251452A1 true WO2021251452A1 (ja) | 2021-12-16 |
Family
ID=78846115
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2021/022048 WO2021251452A1 (ja) | 2020-06-10 | 2021-06-10 | 光線性皮膚疾患の予防又は治療剤 |
Country Status (13)
Country | Link |
---|---|
US (1) | US20230226034A1 (ja) |
EP (1) | EP4166139A4 (ja) |
JP (1) | JPWO2021251452A1 (ja) |
KR (1) | KR20230016008A (ja) |
CN (1) | CN115768428A (ja) |
AR (1) | AR122595A1 (ja) |
AU (2) | AU2021289054B2 (ja) |
BR (1) | BR112022025115A2 (ja) |
CA (1) | CA3186882A1 (ja) |
IL (1) | IL298951A (ja) |
MX (1) | MX2022015806A (ja) |
TW (1) | TW202214240A (ja) |
WO (1) | WO2021251452A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023145959A1 (ja) * | 2022-01-31 | 2023-08-03 | 田辺三菱製薬株式会社 | メラノコルチン1受容体アゴニストの新規用途 |
WO2024029599A1 (ja) * | 2022-08-03 | 2024-02-08 | 田辺三菱製薬株式会社 | 1-{2-[(3s,4r)-1-{[(3r,4r)-1-シクロペンチル-3-フルオロ-4-(4-メトキシフェニル)ピロリジン-3-イル]カルボニル}-4-(メトキシメチル)ピロリジン-3-イル]-5-(トリフルオロメチル)フェニル}ピペリジン-4-カルボン酸もしくはその医薬的に許容し得る塩又は共結晶を含有する医薬組成物 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008025094A1 (en) | 2006-08-31 | 2008-03-06 | Clinuvel Pharmaceuticals Limited | Method of treatment of photodermatoses |
WO2009103816A1 (en) | 2008-02-22 | 2009-08-27 | Clinuvel Pharmaceuticals Limited | Method for treatment of photosensitivity and phototoxicity |
WO2014081845A2 (en) * | 2012-11-21 | 2014-05-30 | University Of Cincinnati | Skin care compositions and methods comprising selective agonists of melanocortin 1 receptor |
JP2014518238A (ja) * | 2011-06-30 | 2014-07-28 | ガルデルマ・リサーチ・アンド・デヴェロップメント | オキサゼチジン誘導体、それらの調製方法並びにヒト医療及び化粧品におけるそれらの使用 |
WO2014160015A1 (en) | 2013-03-13 | 2014-10-02 | Transdermal Biotechnology, Inc. | Skin tanning using peptides and other compositions |
WO2015067503A1 (en) | 2013-11-07 | 2015-05-14 | Clinuvel Ag | Alpha-msh analogues for use in the treatment of psoriasis |
WO2015182723A1 (ja) | 2014-05-29 | 2015-12-03 | 田辺三菱製薬株式会社 | 新規ピロリジン化合物およびメラノコルチン受容体作動薬としての用途 |
JP2017105765A (ja) * | 2015-11-27 | 2017-06-15 | 田辺三菱製薬株式会社 | 医薬組成物 |
WO2018142318A1 (en) | 2017-02-01 | 2018-08-09 | Clinuvel Pharmaceuticals Ltd | Alpha-msh analogues used in the treatment of xeroderma pigmentosum |
WO2020138481A1 (ja) | 2018-12-28 | 2020-07-02 | 田辺三菱製薬株式会社 | ピロリジン化合物の結晶 |
-
2021
- 2021-06-10 CN CN202180041850.4A patent/CN115768428A/zh active Pending
- 2021-06-10 TW TW110121115A patent/TW202214240A/zh unknown
- 2021-06-10 BR BR112022025115A patent/BR112022025115A2/pt unknown
- 2021-06-10 CA CA3186882A patent/CA3186882A1/en active Pending
- 2021-06-10 KR KR1020227045697A patent/KR20230016008A/ko unknown
- 2021-06-10 IL IL298951A patent/IL298951A/en unknown
- 2021-06-10 EP EP21821111.8A patent/EP4166139A4/en active Pending
- 2021-06-10 WO PCT/JP2021/022048 patent/WO2021251452A1/ja active Application Filing
- 2021-06-10 AU AU2021289054A patent/AU2021289054B2/en active Active
- 2021-06-10 US US18/009,128 patent/US20230226034A1/en active Pending
- 2021-06-10 MX MX2022015806A patent/MX2022015806A/es unknown
- 2021-06-10 AR ARP210101589A patent/AR122595A1/es unknown
- 2021-06-10 JP JP2022530614A patent/JPWO2021251452A1/ja active Pending
-
2024
- 2024-06-12 AU AU2024203990A patent/AU2024203990A1/en active Pending
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008025094A1 (en) | 2006-08-31 | 2008-03-06 | Clinuvel Pharmaceuticals Limited | Method of treatment of photodermatoses |
WO2009103816A1 (en) | 2008-02-22 | 2009-08-27 | Clinuvel Pharmaceuticals Limited | Method for treatment of photosensitivity and phototoxicity |
JP2014518238A (ja) * | 2011-06-30 | 2014-07-28 | ガルデルマ・リサーチ・アンド・デヴェロップメント | オキサゼチジン誘導体、それらの調製方法並びにヒト医療及び化粧品におけるそれらの使用 |
WO2014081845A2 (en) * | 2012-11-21 | 2014-05-30 | University Of Cincinnati | Skin care compositions and methods comprising selective agonists of melanocortin 1 receptor |
WO2014160015A1 (en) | 2013-03-13 | 2014-10-02 | Transdermal Biotechnology, Inc. | Skin tanning using peptides and other compositions |
WO2015067503A1 (en) | 2013-11-07 | 2015-05-14 | Clinuvel Ag | Alpha-msh analogues for use in the treatment of psoriasis |
WO2015182723A1 (ja) | 2014-05-29 | 2015-12-03 | 田辺三菱製薬株式会社 | 新規ピロリジン化合物およびメラノコルチン受容体作動薬としての用途 |
JP2017105765A (ja) * | 2015-11-27 | 2017-06-15 | 田辺三菱製薬株式会社 | 医薬組成物 |
WO2018142318A1 (en) | 2017-02-01 | 2018-08-09 | Clinuvel Pharmaceuticals Ltd | Alpha-msh analogues used in the treatment of xeroderma pigmentosum |
WO2020138481A1 (ja) | 2018-12-28 | 2020-07-02 | 田辺三菱製薬株式会社 | ピロリジン化合物の結晶 |
Non-Patent Citations (6)
Title |
---|
ELISABETH I. MINDER, JASMIN BARMAN-AKSOEZEN , XIAOYE SCHNEIDER-YIN : "Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders", CLINICAL PHARMACOKINETICS, vol. 56, no. 8, 6 January 2017 (2017-01-06), pages 815 - 823, XP009541622, ISSN: 0312-5963 * |
KUNISADA ET AL., J INVEST DERMATOL, vol. 137, 2017, pages 1975 |
MINAMI ET AL., J NUTRITION BIOCHEM, vol. 20, 2009, pages 389 |
MORIWAKI ET AL.: "their practice guidelines", J DERMATOL, vol. 44, 2017, pages 1087 |
See also references of EP4166139A4 |
VINOD KUMAR SHARMA ET AL.: "Photodermatoses in Pigmented Skin", PHOTOCHEM PHOTOBIOL SCI, vol. 12, no. 1, January 2013 (2013-01-01), pages 65 - 77 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023145959A1 (ja) * | 2022-01-31 | 2023-08-03 | 田辺三菱製薬株式会社 | メラノコルチン1受容体アゴニストの新規用途 |
WO2024029599A1 (ja) * | 2022-08-03 | 2024-02-08 | 田辺三菱製薬株式会社 | 1-{2-[(3s,4r)-1-{[(3r,4r)-1-シクロペンチル-3-フルオロ-4-(4-メトキシフェニル)ピロリジン-3-イル]カルボニル}-4-(メトキシメチル)ピロリジン-3-イル]-5-(トリフルオロメチル)フェニル}ピペリジン-4-カルボン酸もしくはその医薬的に許容し得る塩又は共結晶を含有する医薬組成物 |
Also Published As
Publication number | Publication date |
---|---|
IL298951A (en) | 2023-02-01 |
TW202214240A (zh) | 2022-04-16 |
AR122595A1 (es) | 2022-09-21 |
AU2021289054A1 (en) | 2023-02-02 |
KR20230016008A (ko) | 2023-01-31 |
AU2021289054B2 (en) | 2024-03-21 |
CA3186882A1 (en) | 2021-12-16 |
EP4166139A4 (en) | 2024-06-26 |
BR112022025115A2 (pt) | 2023-02-07 |
AU2024203990A1 (en) | 2024-07-04 |
EP4166139A1 (en) | 2023-04-19 |
JPWO2021251452A1 (ja) | 2021-12-16 |
MX2022015806A (es) | 2023-03-21 |
CN115768428A (zh) | 2023-03-07 |
US20230226034A1 (en) | 2023-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Shih et al. | Physiology and pathophysiology of renal erythropoietin-producing cells | |
WO2021251452A1 (ja) | 光線性皮膚疾患の予防又は治療剤 | |
AMITAY‐LAISH et al. | Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib | |
Perrella et al. | Transforming growth factor-beta 1, but not dexamethasone, down-regulates nitric-oxide synthase mRNA after its induction by interleukin-1 beta in rat smooth muscle cells. | |
Partyka et al. | Antidepressant-and anxiolytic-like activity of 7-phenylpiperazinylalkyl-1, 3-dimethyl-purine-2, 6-dione derivatives with diversified 5-HT1A receptor functional profile | |
JP2010539078A (ja) | ジメチルフマレートの新規な用途 | |
US20220106297A1 (en) | Photoprotective compositions containing malassezia-derived compounds and/or chemical analogs thereof | |
CA3061703A1 (en) | Novel spiro and cyclic bis-benzylidine proteasome inhibitor for the treatment of cancer, diabetes and neurological disorders | |
US11202748B2 (en) | Photoprotective compositions containing malassezia-derived compounds and/or chemical analogs thereof | |
AU2018385364B2 (en) | C5aR inhibitors for use in the treatment of chemotherapy-induced iatrogenic pain | |
RU2812785C1 (ru) | Профилактическое или терапевтическое средство от фотодерматоза | |
US20190337927A1 (en) | Photoprotective compositions containing malassezia-derived compounds and/or chemical analogs thereof | |
US20190381004A1 (en) | Photoprotective compositions containing malassezia-derived compounds and/or chemical analogs thereof | |
KR101689318B1 (ko) | 에보디아민을 유효성분으로 포함하는 피부노화 예방 또는 치료용 조성물 | |
AU2017316756A1 (en) | Thiohydantoin androgen receptor antagonists for the treatment of cancer | |
US20200276100A1 (en) | Photoprotective compositions containing malassezia-derived compounds and/or chemical analogs thereof | |
AU2021289913A1 (en) | Prophylactic or therapeutic agent for porphyria | |
CN113476432B (zh) | J147在制备治疗和/或预防色素增多性疾病的药物/化妆品的用途 | |
KR20220161172A (ko) | 세노모르픽스용 또는 피부 노화 방지용 조성물 | |
CN115385914B (zh) | 靶向pdcd4的配体小分子在制备抗抑郁药物中的应用 | |
KR20240011630A (ko) | 신규 칼콘 유도체 및 이를 포함하는 아디포사이토카인감소 관련 질환의 예방, 개선 또는 치료용 조성물 | |
JP2023543197A (ja) | Csf1rキナーゼ阻害剤およびその使用 | |
CN118215461A (zh) | 用于减少色素沉着的组合物和方法 | |
KR100782895B1 (ko) | 혈관신생억제용 조성물 | |
Pathania et al. | BBA-Reviews on Cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21821111 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3186882 Country of ref document: CA Ref document number: 2022530614 Country of ref document: JP Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112022025115 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 20227045697 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022134724 Country of ref document: RU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021821111 Country of ref document: EP Effective date: 20230110 |
|
ENP | Entry into the national phase |
Ref document number: 2021289054 Country of ref document: AU Date of ref document: 20210610 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112022025115 Country of ref document: BR Kind code of ref document: A2 Effective date: 20221208 |